B1SP fusion protein therapeutics, methods, and uses

Abstract

Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include a sema domain, a structural stabilization domain; and a half life extending moiety.

Description

FIELD OF THE INVENTION

The present invention relates to compositions and methods for the treatment of cancer. The invention more specifically relates to potential therapeutics for treatment of prostate, lung and breast cancer.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. § 371 national stage entry of International Application No. PCT/CA2016/000182, filed 29 Jun. 2016, which application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/185,772 filed on 29 Jun. 2015, entitled “B1SP FUSION PROTEIN THERAPEUTICS, METHODS, AND USES”, which applications are incorporated herein by reference in their entireties.

BACKGROUND

Among American men, advanced prostate cancer (CaP) is presently the most frequently diagnosed cancer and is the second leading causes of cancer-related deaths. In 2009, an estimated 192,280 American men will be diagnosed with CaP and 27,360 will die of the disease. While early stage disease is frequently curable with surgery or radiation therapy, approximately ⅓ of patients clinically present with locally advanced or metastatic disease that is associated with a poor prognosis. Therapeutic androgen suppression through surgical or medical castration still remains the most effective therapy for advanced CaP since its inception in 1941 by Charles Huggins (Huggins and Hodges 1941). Androgen suppression consistently induces tumour regression in over 80% of patients with advanced disease due to the exquisite dependence of CaP cells on the androgen signaling axis for their growth and survival (Isaacs et al. 1997). Furthermore, Androgen Receptor (AR) expression is maintained throughout prostate cancer progression, and the majority of androgen independent or hormone refractory prostate cancers express AR (Heinlein and Chang 2004). However, despite initial success in achieving significant and tangible clinical responses, the duration of progression-free survival remains transient (˜1-3 years) and progression to lethal castration-resistant disease (also frequently referred to as androgen independent or hormone refractory disease) is essentially universal (Bruchovsky et al. 1988; Goldenberg et al. 1988; Bruchovsky et al. 1989). Thus, the current standard of care for patients with Castration-Resistant Prostate Cancer (CRPC) remains only palliative, with chemotherapy—eg. docetaxel (Petrylak et al. 2004; Tannock et al. 2004) inducing only marginal survival benefits at a cost of, at times, significant morbidity.

Semaphorins are a large family of highly conserved secreted or cell surface signaling proteins that were originally identified as mediators of cell migration and axon guidance in the developing nervous system (Tamagnone and Comoglio 2000; Kruger et al. 2005). While semaphorins have been best characterized in the nervous system, they are known to be expressed in other tissues. Semaphorins have been implicated in a variety of dynamic physiological processes including angiogenesis, tissue morphogenesis, and immunity (Kolodkin et al. 1993; Kruger et al. 2005). Semaphorins regulate numerous biological responses including cell proliferation, adhesion, migration and apoptosis through interaction of semaphorins with their cognate receptors, plexins. Plexins are single pass transmembrane receptors that have highly conserved intracellular domains that have intrinsic GAP (GTPase-activating protein) activity towards R-Ras12 (Negishi et al. 2005). Nine vertebrate plexins have been identified, grouped into four subfamilies (Plexin A to D) based on computational phylogenetic analyses. Semaphorins and plexins both express a conserved 500 amino acid extracellular motif called the SEMA domain that is thought to be involved in protein-protein interactions. Membrane-associated semaphorins bind directly to plexins whereas secreted semaphorins, often have an additional binding component (either neuropilins 1 or 2 (Npn-1 or Npn-2)) as co-receptors. Plexins are thought to regulate the actin cytoskeleton by controlling the activity of the small GTPases, Rnd1, R-Ras, Rac and Rho12. When plexins bind to semaphorin they are thought to also interact with and activate the receptor tyrosine kinases, Her2/neu (ErbB2), and hepatocyte growth factor/scatter factor receptor (c-Met) (Giordano et al. 2002; Swiercz et al. 2004; Swiercz et al. 2008).

SEMA3C is a member of the class 3 semaphorins, which are a subfamily of secreted semaphorins (Tamagnone and Comoglio 2000; Verras et al. 2007). SEMA3C has been shown to bind to receptor complexes comprised of Plexin A1, A2, or B1 in association with either Npn-1 or Npn-210. Plexins can actively influence their binding affinity (and possibly selectivity) for the different subsets of secreted semaphorins. For example, the binding of SEMA3C to neuropilins seems to be inhibited by the co-expression of plexin A1, whereas it is increased in the presence of plexin A2 or B1. Herman and Meadows (2007) suggest an association between SEMA3C expression and increased invasion and adhesion in PC-3 AR negative cancer cells. However, AR negative prostate cancers represent a small minority of late stage androgen independent prostate cancers (Heinlein and Chang 2004). A number of B-type Plexin polypeptides have been suggested as inhibiting the binding of Plexin-B1 and Erb-B2 (U.S. Pat. No. 9,198,966).

SUMMARY

The present invention is based, in part, on the surprising discovery that B1SP fusion proteins inhibit semaphorin-mediated signaling pathways. The present invention is based, in part, on the surprising discovery that B1SP fusion proteins bind to neuropilins and plexins in a dose dependent manner. The present invention is based, in part, on the surprising discovery that B1SP fusion proteins have a potent effect on semaphorin signaling. The present invention is based, in part, on the surprising discovery that B1SP fusion proteins are potent inhibitors of EGFR phosphorylation in prostate cancer cells. The present invention is based, in part, on the surprising discovery that B1SP fusion proteins are inhibitors of R1881-induced proliferation of prostate cancer cells in a dose dependent manner. The present invention is based, in part, on the surprising discovery that B1SP fusion proteins inhibit the association of SEMA3C with NRP1 and PLEXIN B1. The present invention is based, in part, on the surprising discovery that B1SP enhances the interaction of PLEXIN B1 with HER2/ErbB2 in DU145 cells. Furthermore, the present invention is based, in part, on the surprising discovery that B1SP fusion proteins are useful for cancer treatment.

In accordance with a first embodiment, there is provided a method for treating cancer, the method including administering a biologically effective amount of a B1SP fusion protein to cancer cells, wherein the B1SP fusion protein includes: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

In accordance with another embodiment, there is provided a method for killing or inhibiting the proliferation of androgen receptor (AR) positive prostate cancer including contacting the prostate cancer with a biologically effective amount of a composition including a B1SP fusion protein, wherein the B1SP fusion protein includes: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

In accordance with another embodiment, there is provided a method of inhibiting growth of an androgen dependent prostate cancer comprising administering androgen deprivation therapy and a B1SP fusion protein, wherein the B1SP fusion protein comprises: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

In accordance with another embodiment, there is provided a use of a B1SP fusion protein for the manufacture of a medicament to treat cancer, wherein the B1SP fusion protein includes: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

In accordance with another embodiment, there is provided a use of a B1SP fusion protein to treat cancer, wherein the B1SP fusion protein includes: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

In accordance with another embodiment, there is provided a B1SP fusion protein for the treatment of cancer, wherein the B1SP fusion protein includes: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

In accordance with another embodiment, there is provided a pharmaceutical composition comprising a B1SP fusion protein in combination with a physiologically acceptable carrier, wherein the B1SP fusion protein includes: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

In accordance with another embodiment, there is provided a commercial package including a B1SP fusion protein and instructions for its use in the treatment of prostate cancer, wherein the B1SP fusion protein includes: (a) a sema domain; (b) a structural stabilization domain; and (c) a half life extending moiety.

The B1SP fusion protein may further include one or more of a linker and a hinge between the structural stabilization domain and the half life extending domain. The structural stabilization domain may be a Plexins-Semaphorins-Integrins domain (PSI domain). The structural stabilization domain may be a PSI domain from either Plexin B1 or Plexin B2 or Plexin B3. The structural stabilization domain may be SCAQHLDCASCLAHRDPYCG WCVLLGRCSRRSECSRGQGPEQ (SEQ ID NO: 1). The biologically effective amount is an amount sufficient to cause cell death of a cancer cell or to inhibit proliferation of the cancer cell. The cancer cell may be a prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer cell. The cancer cell may be prostate cancer cell. The prostate cancer cell may be an androgen receptor (AR) positive prostate cancer cell. The cancer may be a prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The cancer cell may be prostate cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer.

The half life extending moiety may be selected from: a fragment crystallizable region (Fc region); immunoglobulin-binding domaindomain B (IgBD); Novozymes Albufuse Albumin; serum albumin; ubiquitin; polyethylene glycol (PEG) moiety (PEGylation); Amunix XTEN; an unstructured polymer having a polypeptide backbone; poly-glycine; elastin-like polypeptide; polysialic acid; PASylation (Pro, Ala and Ser (PAS)); glycosylation; HESylation (coupling to hydroxyethyl starch); and Heptune (heparosan conjugation). The half life extending moiety may be selected from: a fragment crystallizable region (Fc region); immunoglobulin-binding domaindomain B (IgBD); Novozymes Albufuse Albumin; serum albumin; and biquitin. The half life extending moiety may be selected from: polyethylene glycol (PEG) moiety (PEGylation); Amunix XTEN; an unstructured polymer having a polypeptide backbone; poly-glycine; elastin-like polypeptide; polysialic acid; PASylation (Pro, Ala and Ser (PAS)); glycosylation; HESylation (coupling to hydroxyethyl starch); and Heptune (heparosan conjugation). The half life extending moiety may be selected from: an Fc region and albumin. The half life extending moiety may be IgBD. The B1SP fusion protein may further include one or more of a linker and a hinge between the structural stabilization domain and the half life extending domain.

The androgen deprivation therapy and the B1SP fusion protein may be initiated at about the same time. The B1SP fusion protein may be initiated after androgen deprivation therapy and before the androgen dependent cancer becomes androgen independent. The androgen deprivation therapy may include administering a luteinizing hormone-releasing hormone (LHRH) analog. The androgen deprivation therapy may include administering anti-androgen treatment. The androgen deprivation therapy may include administering an adrenal androgen inhibitor. The androgen deprivation therapy may be surgical. The androgen deprivation therapy and the SEMA3C inhibitor may be administered with one or more further therapeutic regimen(s). The therapeutic regimen may be a chemotherapeutic regimen. The therapeutic regimen may be a radiotherapeutic regimen.

The B1SP fusion protein may have an amino acid sequence comprising SEQ ID NO:2. The B1SP fusion protein may have an amino acid sequence consisting of SEQ ID NO:2. The B1SP fusion protein may have only one structural stabilization domain. The B1SP fusion protein may have only one PSI domain. The PSI domain may be SCAQHLDCASCLAHRDPYCG WCVLLGRCSRRSECSRGQGPEQ (SEQ ID NO: 1).

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1M show a chromo alignment of sema domains with consensus sequences.

FIGS. 2A-2C show a chromo alignment of structural stabilization domains with consensus sequences.

FIGS. 3A-3H shows that a B1SP fusion protein binds to (FIG. 3A) NRP 1 and (FIG. 3B) Plexin B1 and NRP1 in a dose-dependent manner in DU145 cells in a co-immunoprecipitation assays and in experiments of dose-responses to B1SP treatment the relative amount of B1SP in complex with either (FIG. 3C) NRP1 or (FIG. 3D) Plexin B1 also showed dose-dependent relationships. In FIG. 3E, B1SP EC₅₀ (8.436 nM) were determined using a PE-labelled B1SP (B1SP-PE) which was serially diluted and added to DU145 cells for 1 hour. Cells were washed with DPBS before measurement of PE-Fluorescence intensity (FI). In FIGS. 3F-3H, bar graphs show the Mean and SEM Interactions/cell (FIG. 3F) B1SP binding to PLEXINB1 in DU145 cells, (FIG. 3G) B1SP inhibits the interaction between SEMA3C and NRP1 in DU145 cells and (FIG. 3H) B1SP inhibits the interaction between SEMA3C and PLEXIN B1 in DU145 cells based on photomicrographs of in-situ proximity ligation assay (PLA) results.

FIGS. 4A-4B shows inhibition of EGFR phosphorylation in LNCaP cells are time (FIG. 4A) and dose (FIG. 4B) dependent, where treated cells were harvested and evaluated for the expression of EGFR phosphorylation (pEGFR) and total EGFR expression as compared with anti-vinculin as loading control and untreated cell controls.

FIGS. 5A-5C FIG. 5A shows inhibition of EGFR phosphorylation in LNCaP cells, where the cells were treated with either truncated Semaphorin Fusion proteins (2.0 μM) (ALB SRGLI) or a Plexin B1 Fusion protein (B1SP) (2.0 μM) for 60 minutes followed by stimulation with EGF (10 ng/ml) for 10 min, before the cells were harvested and evaluated for the expression of EGFR phosphorylation (pEGFR), and EGFR levels with a vinculin loading control. FIGS. 5B and 5C show that B1SP inhibits phosphorylation of Shc isoforms downstream of the EGFR.

FIGS. 6A-6C FIG. 6A shows a blot where LNCaP cells when serum starved for 24 hr and then treated simultaneously with a B1SP and Semaphorin 3C:Fc for 60 minutes or a B1SP alone, or Sema3C:Fc alone or where left untreated, followed by stimulation with EGF (10 ng/ml) for 10 min, with resulting levels of EGFR phosphorylation as compared to vinculin as loading control. FIG. 6B shows a Quantitative densitometric analysis of the blot in A and demonstrates that B1SP can inhibit Sema3C-mediated EGFR phosphorylation. Similarly, FIG. 6C shows the inhibition of EGFR phosphorylation in LNCaP, where the LNCaP cells were serum starved, media was then changed and the cells were treated with either truncated Semaphorin Fusion proteins (2.0 μM) (ALB SRGLI and Δ13) and Plexin B1 Fusion protein (B1SP) (2.0 μM) for 60 minutes. Cells were then stimulated with EGF (10 ng/ml) for 10 min and the cells were harvested and evaluated for the expression of EGFR phosphorylation (pEGFR), and EGFR levels. Blots (not shown) were reprobed for Vinculin as loading control and the densitometry analysis EGFR phosphorylation levels was performed.

FIGS. 7A-7F shows inhibition of EGFR phosphorylation in LNCaP and 22RV1 PC cells, wherein EGF-mediated EGFR phosphorylation of LNCaP cells treated with increasing concentration B1SP are shown in FIG. 7A, where the LNCaP cells were serum starved for 24 hours, then treated with the indicated dose (0.5-4.0 μM) of B1SP for one hour followed by stimulation with EGF (10 ng/ml) and the levels of pEGFR, pHER2/ErbB2, pSHC and pMAPK were demonstrated by immunoblotting. In FIG. 7B, the 22RV1 PC cells were serum starved, and a B1SP conditioned medium (CM) was added to the cells for the indicated time-points followed by stimulation with 5.0 ng/ml EGF for 10 minutes, then the cells were harvested and evaluated for the expression of pEGFR, and EGFR as compared to the vinculin loading control and control EGFR phosphorylation evaluated in untreated cells at the termination of the time course. Both FIG. 7A and FIG. 7B show plots of a quantitative densitometric analysis. Similarly, the inhibition of EGFR phosphorylation was tested in 22RV1 PC cells (C), MCF10A normal human mammary cells (FIG. 7D), MR49F PC cells (FIG. 7E) and V16A castration-resistant prostate cancer (CRPC) stem cells (FIG. 7F), with increasing concentrations of B1SP (i.e. 0.5, 1, 2 and 4.0 μM).

FIGS. 8A-D shows that B1SP inhibits PC cell (LNCaP) proliferation in a dose dependent manner with an IC50 of 1.145 μM, where (FIG. 8A) shows cells were treated with synthetic androgen (R1881) as indicated and cell proliferation was evaluated using the PrestoBlue proliferation assay over a period of 5 days; in (FIG. 8B) LNCaP cells were treated with R1881 (1 nM) in combination with increasing concentration B1SP and cell proliferation was monitored over a period of 4 days; (FIG. 8C) shows the inhibitory effect of B1SP on growth expressed as percentage of maximum androgen (R1881) sensitive growth. FIG. 8D shows a plot of B1SP fusion protein dose response on a log scale.

FIGS. 9A-9B shows two plots (two independent experiments) of LNCaP cells that were treated for 48 hours with a purified B1SP fusion protein before cell viability was analyzed using a fluorescence-based live/dead cell viability assay (Calcein/Propidium Iodide).

FIGS. 10A-10B shows a B1SP fusion protein treatment inhibiting adhesion of prostate cancer cells in two types of prostate cancer cells (i.e. (A) LNCaP or (B) DU145 cells), where the cells were pulsed with calcein AM (12.5 μM) and incubated for 30 min, then the cells (1×10⁵) were seeded on precoated, fibronectin (50 μg/ml) in 96-well plates and centrifuged briefly prior to incubation in the presence or absence of a B1SP fusion protein for 16-24 hr. before cell fluorescence was measured (both before and after removal of non-adhered cells by washing). The data represents the average (%) Adhesion of triplicate wells.

FIGS. 11A and 11B show treatment of mice bearing castration resistant C4-2 xenograft tumors with B1SP fusion protein inhibits tumor growth in vivo as shown by decreased tumor volume (FIG. 11A) and serum PSA levels (FIG. 11B) as compared to PBS treated control mice.

FIGS. 12A and 12B show two waterfall plots of percent change in serum PSA levels of individual C4-2 xenograft bearing mice from day 7 to day 14 treated with PBS (n=9) and B1SP (n=7), respectively.

FIG. 13 shows immunoblots of LNCaP and C4-2 prostate cancer cells treated with B1SP stained with Total PARP and Cleaved PARP, which shows that these cells undergo apoptosis.

FIG. 14 shows that B1SP enhances the interaction of PLEXIN B1 with HER2/ErbB2 in DU145 cells, based on PLA analysis using the Duolink in-situ PLA kit.

DETAILED DESCRIPTION

Definitions

A “sema domain” as used herein refers to a distinctive protein domain of approximately 500 amino acids having a 7 blade β propeller, wherein the sema domain may also include one or more long loops and/or insertions, such as an extrusion (Gherardi E. et al. 2004). The sema domain may be from any one of the 1-7 classes of animal semaphorins, viral semaphorin, plexins or from the MET and RON receptor tyrosine kinases (RTKs) as are known in the art. Alternatively, the sema domain may be formed by a combination of 03 propeller blades from one or more different sema domains (see FIG. 1—SEMA DOMAIN CHROMO ALIGNMENT). The Sema domain is characterised by a conserved set of cysteine residues, which form four disulfide bonds to stabilise the structure. The sema domain fold is a variation of the beta propeller topology, with seven blades radially arranged around a central axis. Each blade contains a four-stranded (strands A to D) antiparallel beta sheet. The inner strand of each blade (A) lines the channel at the centre of the propeller, with strands B and C of the same repeat radiating outward, and strand D of the next repeat forming the outer edge of the blade. The large size of the sema domain is not due to a single inserted domain, but results from the presence of additional secondary structure elements inserted in most of the blades. The sema domain uses a ‘loop and hook’ system to close the circle between the first and the last blades. The blades are constructed sequentially with an N-terminal beta-strand closing the circle by providing the outermost strand (D) of the seventh (C-terminal) blade. The beta-propeller is further stabilized by an extension of the N-terminus, providing an additional, fifth beta-strand on the outer edge of blade 6. As used herein an inhibitory sema domain is meant to encompass any sema domain that is capable of inhibiting (1) EGFR phosphorylation, (2) c-Met phosphorylation or (3) VEGFR phosphorylation in cancer cells or inhibiting R1881-induced proliferation, adhesion or cell migration of cancer cells.

A “structural stabilization domain” as used herein refers to a Cystine Rich Domain (CRD) or a Plexins-Semaphorins-Integrins domain (PSI domain). For example, the 1^st PSI domain of Plexin B1 having the sequence, SCAQHLDCASCLAHRDPYCGWCVLLGRCSRRSECSRGQGPEQ (SEQ ID NO:1). Alternative structural stabilization domains are known in the art or may be engineered based on a consensus sequence (see FIG. 2). Alternatively, the structural stabilization domain may be a PSI domain from either Plexin B2 or Plexin B3. Furthermore, the structural stabilization domain should be compatible with the SEMA domain being stabilized. PSI domains or CRDs are cysteine rich domains found in extracellular parts of over 500 signaling proteins. The core structure of a structural stabilization domain consists of a three stranded antiparallel beta-sheet and two alpha-helices.

The source (i.e. animal origin) of the SEMA domain and/or the structural stabilization domain may have implications for the development of human therapeutic proteins. For example, the differences in amino acid sequence between the source and the human sequence may lead to increased risk of immunogenicity of the therapeutic protein.

A “half life extending moiety” as used herein refers to any moiety that prolongs the half life of the fusion protein within a subject (Hutt M. et al. The Journal of Biological Chemistry (2012) 287(7):4462-4469). For example, a fragment crystallizable region (Fc region); immunoglobulin-binding domain (IgBD) B; Novozymes™ Albufuse™ Albumin; serum albumin; ubiquitin; chemical attachment of a polyethylene glycol (PEG) moiety or PEGylation; Amunix™ XTEN™ product which comprises a long, hydrophilic, and unstructured polymer having a polypeptide backbone. Furthermore, half-life may be extended by conjugation to poly-glycine, elastin-like polypeptide, and polysialic acid. PASylation is another strategy for extending half life of proteins by addition of conformationally disordered polypeptide chains with expanded hydrodynamic volume comprising the small residues Pro, Ala and Ser (PAS). Alteration of glycosylation, HESylation (coupling to hydroxyethyl starch) and Heptune (heparosan conjugation) are other methods for half life extension. The half life extending domain may be suitable for use with both monomers (for example, albumin) or dimers (for example, fc region)).

The fragment crystallizable region (Fc region) as used herein is the tail region of an antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system. This property allows antibodies to activate the immune system. In IgG, IgA and IgD antibody isotypes, the Fc region is composed of two identical protein fragments, derived from the second and third constant domains of the antibody's two heavy chains; IgM and IgE Fc regions contain three heavy chain constant domains (CH domains 2-4) in each polypeptide chain.

A “Linker” as used herein refers to short peptide sequences that occur between protein domains. Linkers are often composed of flexible residues like glycine and serine so that the adjacent protein domains are free to move relative to one another. Longer linkers are used when it is necessary to ensure that two adjacent domains do not sterically interfere with one another. When two different proteins or peptides are linked, linkers are often also added, to make it more likely that the proteins fold independently and behave as expected.

Alternatively, linkers may enable protein purification or linkers in protein or peptide fusions are sometimes engineered with cleavage sites for proteases or chemical agents that enable the liberation of the two separate proteins.

A “Hinge” as used herein refers to the hinge fragment, which acts as a pivot in native immunoglobulins. The hinge is a flexible amino acid stretch in the central part of the heavy chains of the IgG and IgA immunoglobulin classes, which links these 2 chains by disulfide bonds. The hinge is particularly rich in cysteine and proline amino acids, may be extremely variable in amino acid sequence, and does not resemble other immunoglobulin regions. A portion of the IgM heavy chain has similar properties to the gamma hinge. The three-dimensional structure of the hinge region (225-232/225′-232′) in synthetic peptide vaccines is identical to that of the fragment in the native protein, so the subdomain character of the IgG fragment is retained even upon N- and C-terminal elongation with peptide sequences unrelated to IgG.

“Systemic delivery,” as used herein, may refer to delivery of lipid particles or other carriers that leads to a broad biodistribution of a B1SP fusion protein within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. To obtain broad biodistribution generally requires a blood lifetime such that the agent is not rapidly degraded or cleared (such as by first pass organs (liver, lung, etc.) or by rapid, nonspecific cell binding) before reaching a disease site distal to the site of administration. Systemic delivery of a B1SP fusion protein can be by any means known in the art including, for example, intravenous, subcutaneous, and intraperitoneal. In an embodiment, systemic delivery of a B1SP fusion protein is by intravenous delivery.

“Local delivery,” as used herein, refers to delivery of a B1SP fusion protein directly to a target site within an organism. For example, a B1SP fusion protein can be locally delivered by direct injection into a disease site, other target site, or a target organ such as the prostate.

As used herein, an “inhibitor” refers to an agent that restrains, retards, or otherwise causes inhibition of a physiological, chemical or enzymatic action or function. An inhibitor may cause at least 5% decrease in enzyme activity. An inhibitor may also refer to a drug, compound or agent that prevents or reduces the expression, transcription or translation of a gene or protein. An inhibitor may reduce or prevent the function of a protein, for instance by binding to and/or activating/inactivating another protein or receptor. An inhibitor may reduce or prevent the interaction of an enzyme or protein with another enzyme or protein. An inhibitor may cause degradation or clearance of a protein from a cell or from the body of a subject. For instance, an inhibitor may bind to the protein and such binding may target the protein for cellular degradation or for clearance from the body. Binding of an inhibitor may prevent it from binding its cognate receptor, could prevent other important molecular interactions, or could alter the conformation of the protein. Binding of an inhibitor to the receptor of the protein may also prevent interaction of the protein with the receptor, and would thus also inhibit the cellular function of the protein in question. Such an inhibitor may be a B1SP fusion protein as described herein. All such embodiments are considered within the definition of an inhibitor and are considered to be within the scope of the present invention.

The terms “peptide”, “polypeptide” and “protein” may be used interchangeably, and refer to a compound comprised of at least two amino acid residues covalently linked by peptide bonds or modified peptide bonds, for example peptide isosteres (modified peptide bonds) that may provide additional desired properties to the peptide, such as increased half-life. A peptide may comprise at least two amino acids. The amino acids comprising a peptide or protein described herein may also be modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art.

Modifications can occur anywhere in a peptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It is understood that the same type of modification may be present in the same or varying degrees at several sites in a given peptide.

Examples of modifications to peptides may include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, Proteins-Structure and Molecular Properties, 2^nd ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold F, Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in Posttranslational Covalent Modification of Proteins, B. C. Johnson, ed., Academic Press, New York, 1983; Seifter et al., Analysis for protein modifications and nonprotein cofactors, Meth. Enzymol. (1990) 182: 626-646 and Rattan et al. (1992), Protein Synthesis: Posttranslational Modifications and Aging,” Ann NY Acad Sci 663: 48-62.

A “substantially similar sequence” refers to an amino acid sequence that differs from a reference sequence only by one or more substitutions, but which may, for example, be functionally homologous to another substantially similar sequence. It will be appreciated by a person of skill in the art the aspects of the individual amino acids in a peptide of the invention that may be substituted.

Amino acid sequence similarity or identity may be computed by using the BLASTP and TBLASTN programs which employ the BLAST (basic local alignment search tool) 2.0 algorithm. Techniques for computing amino acid sequence similarity or identity are well known to those skilled in the art, and the use of the BLAST algorithm is described in ALTSCHUL et al. 1990, J Mol. Biol. 215: 403-410 and ALTSCHUL et al. (1997), Nucleic Acids Res. 25: 3389-3402.

Amino acids may be described as, for example, polar, non-polar, acidic, basic, aromatic or neutral. A polar amino acid is an amino acid that may interact with water by hydrogen bonding at biological or near-neutral pH. The polarity of an amino acid is an indicator of the degree of hydrogen bonding at biological or near-neutral pH. Examples of polar amino acids include serine, proline, threonine, cysteine, asparagine, glutamine, lysine, histidine, arginine, aspartate, tyrosine and glutamate. Examples of non-polar amino acids include glycine, alanine, valine leucine, isoleucine, methionine, phenylalanine, and tryptophan. Acidic amino acids have a net negative charge at a neutral pH. Examples of acidic amino acids include aspartate and glutamate. Basic amino acids have a net positive charge at a neutral pH. Examples of basic amino acids include arginine, lysine and histidine. Aromatic amino acids are generally nonpolar, and may participate in hydrophobic interactions. Examples of aromatic amino acids include phenylalanine, tyrosine and tryptophan. Tyrosine may also participate in hydrogen bonding through the hydroxyl group on the aromatic side chain. Neutral, aliphatic amino acids are generally nonpolar and hydrophobic. Examples of neutral amino acids include alanine, valine, leucine, isoleucine and methionine. An amino acid may be described by more than one descriptive category. Amino acids sharing a common descriptive category may be substitutable for each other in a peptide.

Nomenclature used to describe the peptide compounds of the present invention follows the conventional practice where the amino group is presented to the left and the carboxy group to the right of each amino acid residue. In the sequences representing selected specific embodiments of the present invention, the amino- and carboxy-terminal groups, although not specifically shown, will be understood to be in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue may be generally represented by a one-letter or three-letter designation, corresponding to the trivial name of the amino acid, in accordance with Table 1.

TABLE 1
Nomenclature and abbreviations of the 20 standard L-amino
acids commonly found in naturally occurring peptides.
Full name	Three-letter abbreviation	One-letter abbreviation
Alanine	Ala	A
Cysteine	Cys	C
Aspartic acid	Asp	D
Glutamic acid	Glu	E
Phenylalanine	Phe	F
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Lysine	Lys	K
Leucine	Leu	L
Methionine	Met	M
Asparagine	Asp	N
Proline	Pro	P
Glutamine	Gln	Q
Arginine	Arg	R
Serine	Ser	S
Threonine	Thr	T
Valine	Val	V
Tryptophan	Trp	W
Tyrosine	Tyr	T

The hydropathy index of an amino acid is a scale indicating the tendency of an amino acid to seek out an aqueous environment (negative value) or a hydrophobic environment (positive value) (KYTE & DOOLITTLE 1982. J Mol Biol 157:105-132). Hydropathy indices of the standard amino acids include alanine (1.8), arginine (−4.5), asparagine (−3.5), aspartic acid (−3.5), cysteine (2.5), glutamine (−3.5), glutamic acid (−3.5), glycine (−0.4), histidine (−3.2), isoleucine (4.5), leucine (3.8), lysine (−3.9), methionine (1.9), phenylalanine (2.8), proline (−1.6), serine (−0.8), threonine (−0.7), tryptophan (−0.9), tyrosine (−1.3), and valine (4.2). Amino acids with similar hydropathy indices may be substitutable for each other in a peptide.

In order to further exemplify what is meant by a conservative amino acid substitution, Groups A-F are listed below. The replacement of one member of the following groups by another member of the same group is considered to be a conservative substitution.

Group A includes leucine, isoleucine, valine, methionine, phenylalanine, serine, cysteine, threonine, and modified amino acids having the following side chains: ethyl, iso-butyl, —CH₂CH₂OH, —CH₂CH₂CH₂OH, —CH₂CHOHCH₃ and CH₂SCH₃.

Group B includes glycine, alanine, valine, serine, cysteine, threonine, and a modified amino acid having an ethyl side chain.

Group C includes phenylalanine, phenylglycine, tyrosine, tryptophan, cyclohexylmethyl, and modified amino residues having substituted benzyl or phenyl side chains.

Group D includes glutamic acid, aspartic acid, a substituted or unsubstituted aliphatic, aromatic or benzylic ester of glutamic or aspartic acid (e.g., methyl, ethyl, n-propyl, iso-propyl, cyclohexyl, benzyl, or substituted benzyl), glutamine, asparagine, CO—NH-alkylated glutamine or asparagine (e.g., methyl, ethyl, n-propyl, and iso-propyl), and modified amino acids having the side chain —(CH₂)₃COOH, an ester thereof (substituted or unsubstituted aliphatic, aromatic, or benzylic ester), an amide thereof, and a substituted or unsubstituted N-alkylated amide thereof.

Group E includes histidine, lysine, arginine, N-nitroarginine, p-cycloarginine, g-hydroxyarginine, N-amidinocitruline, 2-amino guanidinobutanoic acid, homologs of lysine, homologs of arginine, and ornithine.

Group F includes serine, threonine, cysteine, and modified amino acids having C1-C5 straight or branched alkyl side chains substituted with —OH or —SH.

Groups A-F are exemplary and are not intended to limit the invention.

Peptides or peptide analogues can be synthesised by chemical techniques known in the art, for example, by automated synthesis using solution or solid phase synthesis methodology. Automated peptide synthesisers are commercially available and use techniques well known in the art. Peptides and peptide analogues can also be prepared using recombinant DNA technology using methods such as those described in, for example, SAMBROOK J. AND RUSSELL D. (2000) Molecular Cloning: A Laboratory Manual (Third Edition) Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) or AUSUBEL et al. (Current Protocols in Molecular Biology, John Wiley & Sons, 1994).

A “peptidomimetic” is a compound comprising non-peptidic structural elements that mimics the biological action of a parent peptide. A peptidomimetic may not have classical peptide characteristics such as an enzymatically scissile peptidic bond. A parent peptide may initially be identified as a binding sequence or phosphorylation site on a protein of interest, or may be a naturally occurring peptide, for example a peptide hormone. Assays to identify peptidomimetics may include a parent peptide as a positive control for comparison purposes, when screening a library, such as a peptidomimetic library. A peptidomimetic library is a library of compounds that may have biological activity similar to that of a parent peptide.

Amino acids contained within the peptides described herein will be understood to be in the L- or D-configuration. In peptides and peptidomimetics of the present invention, D-amino acids may be substitutable for L-amino acids. Amino acids contained within the peptides of the present invention, and particularly at the carboxy- or amino-terminus, may be modified by methylation, amidation, acetylation or substitution with other chemical groups which may change the circulating half-life of the peptide without adversely affecting their biological activity. Additionally, a disulfide linkage may be present or absent in the peptides of the invention. Another approach for modification of an existing sequence is to synthesize the corresponding retro-inverso version. A retro-inverso peptide is one in which the sequence is reversed ie. reversal of the N to C terminal and synthesized using D-amino acids. Retro inverso analogs of L peptides when aligned alongside each other from N to C and C to N have all side chains in the same orientation, however the peptide bonds are reversed and sterically unavailable for cleavage by proteases. Nair et. al. 2003 J. Immunol. 170:1362-1373.

“Peptide nucleic acids” (PNA) as used herein refer to modified nucleic acids in which the sugar phosphate skeleton of a nucleic acid has been converted to an N-(2-aminoethyl)-glycine skeleton. Although the sugar-phosphate skeletons of DNA/RNA are subjected to a negative charge under neutral conditions resulting in electrostatic repulsion between complementary chains, the backbone structure of PNA does not inherently have a charge. Therefore, there is no electrostatic repulsion. Consequently, PNA has a higher ability to form double strands as compared with conventional nucleic acids, and has a high ability to recognize base sequences. Furthermore, PNAs are generally more robust than nucleic acids. PNAs may also be used in arrays and in other hybridization or other reactions as described above and herein for oligonucleotides.

As used herein, the term “vector” refers to a polynucleotide compound used for introducing exogenous or endogenous polynucleotide into host cells. A vector comprises a nucleotide sequence, which may encode one or more polypeptide molecules. Plasmids, cosmids, viruses and bacteriophages, in a natural state or which have undergone recombinant engineering, are non-limiting examples of commonly used vectors to provide recombinant vectors comprising at least one desired isolated polynucleotide molecule.

The nucleic acid molecules can be inserted into any suitable vector. Suitable vectors include, without limitation, viral vectors. Suitable viral vectors include, without limitation, retroviral vectors, alphaviral, vaccinial, adenoviral, adenoassociated viral, herpes viral, and fowl pox viral vectors. The vectors preferably have a native or engineered capacity to transform eukaryotic cells, e.g., CHO-K1 cells. Additionally, the vectors useful in the context of the invention can be “naked” nucleic acid vectors (i.e., vectors having little or no proteins, sugars, and/or lipids encapsulating them) such as plasmids or episomes, or the vectors can be complexed with other molecules. Other molecules that can be suitably combined with the inventive nucleic acids include without limitation viral coats, cationic lipids, liposomes, polyamines, gold particles, and targeting moieties such as ligands, receptors, or antibodies that target cellular molecules.

Nonstandard amino acids may occur in nature, and may or may not be genetically encoded. Examples of genetically encoded nonstandard amino acids include selenocysteine, sometimes incorporated into some proteins at a UGA codon, which may normally be a stop codon, or pyrrolysine, sometimes incorporated into some proteins at a UAG codon, which may normally be a stop codon. Some nonstandard amino acids that are not genetically encoded may result from modification of standard amino acids already incorporated in a peptide, or may be metabolic intermediates or precursors, for example. Examples of nonstandard amino acids include 4-hydroxyproline, 5-hydroxylysine, 6-N-methyllysine, gamma-carboxyglutamate, desmosine, selenocysteine, ornithine, citrulline, lanthionine, 1-aminocyclopropane-1-carboxylic acid, gamma-aminobutyric acid, carnitine, sarcosine, or N-formylmethionine. Synthetic variants of standard and non-standard amino acids are also known and may include chemically derivatized amino acids, amino acids labeled for identification or tracking, or amino acids with a variety of side groups on the alpha carbon. Examples of such side groups are known in the art and may include aliphatic, single aromatic, polycyclic aromatic, heterocyclic, heteronuclear, amino, alkylamino, carboxyl, carboxamide, carboxyl ester, guanidine, amidine, hydroxyl, alkoxy, mercapto-, alkylmercapto-, or other heteroatom-containing side chains. Other synthetic amino acids may include alpha-imino acids, non-alpha amino acids such as beta-amino acids, des-carboxy or des-amino acids. Synthetic variants of amino acids may be synthesized using general methods known in the art, or may be purchased from commercial suppliers, for example RSP Amino Acids LLC (Shirley, Mass.).

The B1SP fusion proteins described herein may be in isolation, or may be linked to or in combination with tracer compounds, liposomes, carbohydrate carriers, polymeric carriers or other agents or excipients as will be apparent to one of skill in the art. In an alternate embodiment, such compounds may comprise a medicament, wherein such compounds may be present in a pharmacologically effective amount.

The term “medicament” as used herein refers to a composition that may be administered to a patient or test subject and is capable of producing an effect in the patient or test subject. The effect may be chemical, biological or physical, and the patient or test subject may be human, or a non-human animal, such as a rodent or transgenic mouse, or a dog, cat, cow, sheep, horse, beaver, hamster, guinea pig, rabbit or pig. The medicament may be comprised of the effective chemical entity alone or in combination with a pharmaceutically acceptable excipient.

The term “pharmaceutically acceptable excipient” may include any and all solvents, dispersion media, coatings, antibacterial, antimicrobial or antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. An excipient may be suitable for intravenous, intraperitoneal, intramuscular, subcutaneous, intrathecal, topical or oral administration. An excipient may include sterile aqueous solutions or dispersions for extemporaneous preparation of sterile injectable solutions or dispersion. Use of such media for preparation of medicaments is known in the art.

B1SP fusion proteins described herein may be administered in any of a variety of known routes. Examples of methods that may be suitable for the administration of a B1SP fusion protein described herein include orally, intravenous, inhalation, intramuscular, subcutaneous, topical, intraperitoneal, intra-rectal or intra-vaginal suppository, sublingual, and the like. A B1SP fusion protein as described herein may be administered as a sterile aqueous solution, or may be administered in a fat-soluble excipient, or in another solution, suspension, patch, tablet or paste format as is appropriate. A composition comprising the B1SP fusion protein described herein may be formulated for administration by inhalation. For instance, a B1SP fusion protein described herein may be combined with an excipient to allow dispersion in an aerosol. Examples of inhalation formulations will be known to those skilled in the art. Other agents may be included in combination with the B1SP fusion protein described herein to aid uptake or metabolism, or delay dispersion within the host, such as in a controlled-release formulation. Examples of controlled release formulations will be known to those of skill in the art, and may include microencapsulation, embolism within a carbohydrate or polymer matrix, and the like. Other methods known in the art for making formulations are found in, for example, “Remington's Pharmaceutical Sciences”, (19th edition), ed. A. Gennaro, 1995, Mack Publishing Company, Easton, Pa.

The dosage of a B1SP fusion protein described herein may vary depending on the route of administration (oral, intravenous, inhalation, or the like) and the form in which the composition or compound is administered (solution, controlled release or the like). Determination of appropriate dosages is within the ability of one of skill in the art. As used herein, an “effective amount”, a “therapeutically effective amount”, or a “pharmacologically effective amount” of a medicament refers to an amount of a medicament present in such a concentration to result in a therapeutic level of drug delivered over the term that the drug is used. This may be dependent on mode of delivery, time period of the dosage, age, weight, general health, sex and diet of the subject receiving the medicament. Methods of determining effective amounts are known in the art. It is understood that it could be potentially beneficial to restrict delivery of a B1SP fusion protein is described herein to the target tissue or cell in which administration is desired. It is also understood that it may be desirable to target a B1SP fusion protein described herein to a desired tissue or cell type. The B1SP fusion protein described herein of the invention may be coupled to a cell uptake moiety. The targeting moiety may also function as the cell uptake moiety.

Delivery of bioactive molecules such as peptides, to a cell or cells in a reasonably efficient manner may require more than just the ‘dumping’ of the naked peptide onto the cell, or administering the naked peptide into the patient or test subject. Agents that enable delivery of bioactive molecules into cells in a suitable manner so as to provide an effective amount, such as a pharmacologically effective amount are known in the art, and are described in, for example, DIETZ et al 2004. Mol Cell. Neurosci 27:85-131. Examples of such agents include liposomes, lipid particles, antibodies or receptor ligands that may be coupled to the bioactive molecule, viral vectors, and protein transduction domains (PTD). Examples of PTDs include Antennapedia homeodomain (PEREZ et al 1992 J. Cell Sci 102:717-722), transportan (POOGA et al 1998 FASEB J 12: 67-77), the translocation domains of diphtheria toxin (STENMARK et al 1991 J Cell Biol 113:1025-1032; WIEDLOCHA et al 1994 Cell 76:1039-1051), anthrax toxin (BALLARD et al 1998 Infect. Immun 66:615-619; BLANKE et al 1996 Proc Natl Acad Sci 93: 8437-8442) and Pseudomonas exotoxin A (PRIOR et al 1992 Biochemistry 31:3555-3559), protegrin derivatives such as dermaseptin S4 (HARITON-GAZAL et al 2002 Biochemistry 41:9208-9214), HSV-1 VP22 (DILBER et al 1999 Gene Ther. 6:12-21), PEP-1 (MORRIS et al 2001 Nature Biotechnol 19:1173-1176), basic peptides such as poly-L and poly-D-lysine (WOLFERT et al 1996 Gene Ther. 3:269-273; RYSER et al 1980 Cancer 45:1207-1211; SHEN et al 1978 Proc Natl Acad Sci 75:1872-1876), HSP70 (FUJIHARA et al 1999 EMBO J 18:411-419) and HIV-TAT (DEMARCHI et al 1996 J Virol 70:4427-4437). Other examples and related details of such protein transduction domains are described in DIETZ, supra and references therein.

As used herein, the term “cancer” refers to a proliferative disorder caused or characterized by the proliferation of cells which have lost susceptibility to normal growth control. The term cancer, as used in the present application, includes tumors and any other proliferative disorders, such as prostate adenocarcinoma. Cancers of the same tissue type usually originate in the same tissue, and may be divided into different subtypes based on their biological characteristics. Four general categories of cancers are carcinoma (epithelial tissue derived), sarcoma (connective tissue or mesodermal derived), leukemia (blood-forming tissue derived) and lymphoma (lymph tissue derived). Over 200 different types of cancers are known, and every organ and tissue of the body may be affected. Specific examples of cancers that do not limit the definition of cancer may include melanoma, leukemia, astrocytoma, glioblastoma, retinoblastoma, lymphoma, glioma, Hodgkins' lymphoma and chronic lymphocyte leukemia. Examples of organs and tissues that may be affected by various cancers include pancreas, breast, thyroid, ovary, uterus, testis, prostate, thyroid, pituitary gland, adrenal gland, kidney, stomach, esophagus, colon or rectum, head and neck, bone, nervous system, skin, blood, nasopharyngeal tissue, lung, urinary tract, cervix, vagina, exocrine glands and endocrine glands. Alternatively, a cancer may be multicentric or of unknown primary site (CUPS). The cancer may be selected from the group including: prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma and endometrial cancer. The cancer may be prostate cancer.

As used herein, a “cancerous cell” refers to a cell that has undergone a transformation event and whose growth is no longer regulated to the same extent as before said transformation event. A tumor refers to a collection of cancerous cells, often found as a solid or semi-solid lump in or on the tissue or a patient or test subject.

A cancer or cancerous cell may be described as “sensitive to” or “resistant to” a given therapeutic regimen or chemotherapeutic agent based on the ability of the regimen to kill cancer cells or decrease tumor size, reduce overall cancer growth (i.e. through reduction of angiogenesis), and/or inhibit metastasis. Cancer cells that are resistant to a therapeutic regimen may not respond to the regimen and may continue to proliferate. Cancer cells that are sensitive to a therapeutic regimen may respond to the regimen resulting in cell death, a reduction in tumor size, reduced overall growth (tumor burden) or inhibition of metastasis. For example, this desirably manifest itself in a reduction in tumor size, overall growth/tumor burden or the incidence of metastasis of about 10% or more, for example, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or more, to about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold or more. Monitoring of a response may be accomplished by numerous pathological, clinical and imaging methods as described herein and known to persons of skill in the art.

A common theme for a chemotherapeutic agent or combination of agents is to induce death of the cancerous cells. For example, DNA adducts such as nitrosoureas, busulfan, thiotepa, chlorambucil, cisplatin, mitomycin, procarbazine, or dacacarbazine slow the growth of the cancerous cell by forcing the replicating cell to repair the damaged DNA before the M-phase of the cell cycle, or may by themselves cause sufficient damage to trigger apoptosis of the cancerous cell. Other events such as gene expression or transcription, protein translation, or methylation of the replicated DNA, for example, may also be interfered with by the varied arsenal of chemotherapeutic agents available to the clinician and help to trigger apoptotic processes within the cancerous cells. Alternately, a chemotherapeutic agent may enable the cancerous cell to be killed by aspects of the patient or test subject's humoral or acquired immune system, for example, the complement cascade or lymphocyte attack.

The method for treating prostate cancer comprising administering a biologically effective amount of a B1SP fusion protein to cancer cells may be supplemented with a further therapeutic regimen. As used herein, a “therapeutic regimen” or “therapy” refers to the administration of at least one additional agent (i.e. other than the B1SP fusion protein) which is harmful to cancerous cells. Suitable therapeutic regimens for use in accordance with the invention include, but are not limited to, “chemotherapeutic regimens,” “radiotherapeutic regimens,” “alternative therapeutic regimen” and combinations thereof.

As used herein, a “chemotherapeutic regimen” or “chemotherapy” refers to the administration of at least one chemotherapy agent which is harmful to destroy cancerous cells. There are a myriad of such chemotherapy agents available to a clinician.

Chemotherapy agents may be administered to a subject in a single bolus dose, or may be administered in smaller doses over time. A single chemotherapeutic agent may be used (single-agent therapy) or more than one agent may be used in combination (combination therapy). Chemotherapy may be used alone to treat some types of cancer. Alternatively, chemotherapy may be used in combination with other types of treatment, for example, radiotherapy or alternative therapies (for example immunotherapy) as described herein. Additionally, a chemosensitizer may be administered as a combination therapy with a chemotherapy agent.

As used herein, a “chemotherapeutic agent” refers to a medicament that may be used to treat cancer, and generally has the ability to kill cancerous cells directly. Examples of chemotherapeutic agents include alkylating agents, antimetabolites, natural products, hormones and antagonists, and miscellaneous agents. Examples of alternate names are indicated in brackets. Examples of alkylating agents include nitrogen mustards such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin) and chlorambucil; ethylenimines and methylmelamines such as hexamethylmelamine and thiotepa; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine (BCNU), semustine (methyl-CCNU), lomustine (CCNU) and streptozocin (streptozotocin); DNA synthesis antagonists such as estramustine phosphate; and triazines such as dacarbazine (DTIC, dimethyl-triazenoimidazolecarboxamide) and temozolomide. Examples of antimetabolites include folic acid analogs such as methotrexate (amethopterin); pyrimidine analogs such as fluorouracin (5-fluorouracil, 5-FU, 5FU), floxuridine (fluorodeoxyuridine, FUdR), cytarabine (cytosine arabinoside) and gemcitabine; purine analogs such as mercaptopurine (6-mercaptopurine, 6-MP), thioguanine (6-thioguanine, TG) and pentostatin (2′-deoxycoformycin, deoxycoformycin), cladribine and fludarabine; and topoisomerase inhibitors such as amsacrine. Examples of natural products include vinca alkaloids such as vinblastine (VLB) and vincristine; taxanes such as paclitaxel and docetaxel (Taxotere); epipodophyllotoxins such as etoposide and teniposide; camptothecins such as topotecan and irinotecan; antibiotics such as dactinomycin (actinomycin D), daunorubicin (daunomycin, rubidomycin), doxorubicin, bleomycin, mitomycin (mitomycin C), idarubicin, epirubicin; enzymes such as L-asparaginase; and biological response modifiers such as interferon alpha and interlelukin 2. Examples of hormones and antagonists include luteinising releasing hormone agonists such as buserelin; adrenocorticosteroids such as prednisone and related preparations; progestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogens such as diethylstilbestrol and ethinyl estradiol and related preparations; estrogen antagonists such as tamoxifen and anastrozole; androgens such as testosterone propionate and fluoxymesterone and related preparations; androgen antagonists such as flutamide and bicalutamide; and gonadotropin-releasing hormone analogs such as leuprolide. Examples of miscellaneous agents include thalidomide; platinum coordination complexes such as cisplatin (cis-DDP), oxaliplatin and carboplatin; anthracenediones such as mitoxantrone; substituted ureas such as hydroxyurea; methylhydrazine derivatives such as procarbazine (N-methylhydrazine, MIH); adrenocortical suppressants such as mitotane (o,p′-DDD) and aminoglutethimide; RXR agonists such as bexarotene; and tyrosine kinase inhibitors such as imatinib. Alternate names and trade-names of these and additional examples of chemotherapeutic agents, and their methods of use including dosing and administration regimens, will be known to a person versed in the art, and may be found in, for example “The Pharmacological basis of therapeutics”, 10^th edition. HARDMAN H G., LIMBIRD L E. editors. McGraw-Hill, New York, and in “Clinical Oncology”, 3^rd edition. Churchill Livingstone/Elsevier Press, 2004. ABELOFF, M D. editor. In particular, suitable chemotherapeutic agents for use in accordance with the invention include, without limitation, nanoparticle albumin-bound paclitaxels.

As used herein, the term “radiotherapeutic regimen” or “radiotherapy” refers to the administration of radiation to kill cancerous cells. Radiation interacts with various molecules within the cell, but the primary target, which results in cell death is the deoxyribonucleic acid (DNA). However, radiotherapy often also results in damage to the cellular and nuclear membranes and other organelles. DNA damage usually involves single and double strand breaks in the sugar-phosphate backbone. Furthermore, there can be cross-linking of DNA and proteins, which can disrupt cell function. Depending on the radiation type, the mechanism of DNA damage may vary as does the relative biologic effectiveness. For example, heavy particles (i.e. protons, neutrons) damage DNA directly and have a greater relative biologic effectiveness. Electromagnetic radiation results in indirect ionization acting through short-lived, hydroxyl free radicals produced primarily by the ionization of cellular water. Clinical applications of radiation consist of external beam radiation (from an outside source) and brachytherapy (using a source of radiation implanted or inserted into the patient). External beam radiation consists of X-rays and/or gamma rays, while brachytherapy employs radioactive nuclei that decay and emit alpha particles, or beta particles along with a gamma ray.

Radiotherapy may further be used in combination chemotherapy, with the chemotherapeutic agent acting as a radiosensitizer. The specific choice of radiotherapy suited to an individual patient may be determined by a skilled person at the point of care, taking into consideration the tissue and stage of the cancer. Examples of radiotherapy approaches to various cancers may be found in, for example “Clinical Oncology”, 3^rd edition. Churchill Livingstone/Elsevier Press, 2004. ABELOFF, M D. editor.

As used herein, the term “alternative therapeutic regimen” or “alternative therapy” may include for example, biologic response modifiers (including polypeptide-, carbohydrate-, and lipid-biologic response modifiers), toxins, lectins, antiangiogenic agents, receptor tyrosine kinase inhibitors (for example Iressa™ (gefitinib), Tarceva™ (erlotinib), Erbitux™ (cetuximab), imatinib mesilate (Gleevec™), proteosome inhibitors (for example bortezomib, Velcade™); VEGFR2 inhibitors such as PTK787 (ZK222584), aurora kinase inhibitors (for example ZM447439); mammalian target of rapamycin (mTOR) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, rapamycin inhibitors (for example sirolimus, Rapamune™); farnesyltransferase inhibitors (for example tipifarnib, Zarnestra); matrix metalloproteinase inhibitors (for example BAY 12-9566; sulfated polysaccharide tecogalan); angiogenesis inhibitors (for example Avastin™ (bevacizumab); analogues of fumagillin such as TNP-4; carboxyaminotriazole; BB-94 and BB-2516; thalidomide; interleukin-12; linomide; peptide fragments; and antibodies to vascular growth factors and vascular growth factor receptors); platelet derived growth factor receptor inhibitors, protein kinase C inhibitors, mitogen-activated kinase inhibitors, mitogen-activated protein kinase kinase inhibitors, Rous sarcoma virus transforming oncogene (SRC) inhibitors, histonedeacetylase inhibitors, small hypoxia-inducible factor inhibitors, hedgehog inhibitors, and TGF-β signalling inhibitors. Furthermore, an immunotherapeutic agent would also be considered an alternative therapeutic regimen. Examples include chemokines, chemotaxins, cytokines, interleukins, or tissue factor. Suitable immunotherapeutic agents also include serum or gamma globulin containing preformed antibodies; nonspecific immunostimulating adjuvants; active specific immunotherapy; and adoptive immunotherapy. In addition, alternative therapies may include other biological-based chemical entities such as polynucleotides, including antisense molecules, polypeptides, antibodies, gene therapy vectors and the like. Such alternative therapeutics may be administered alone or in combination, or in combination with other therapeutic regimens described herein. Alternate names and trade-names of these agents used in alternative therapeutic regimens and additional examples of agents used in alternative therapeutic regimens, and their methods of use including dosing and administration regimens, will be known to a physician versed in the art. Furthermore, methods of use of chemotherapeutic agents and other agents used in alternative therapeutic regimens in combination therapies, including dosing and administration regimens, will also be known to a person versed in the art.

Prostate Cancer

The Semaphorins belong to a family of secreted and membrane bound proteins that contain a conserved SEMA domain. Semaphorins and their receptors (mainly plexins and neuropilins) are aberrantly expressed in human tumors. Semaphorin signals have an important role in the regulation of tumor angiogenesis, invasion and metastasis. The present disclosure details the use of a B1SP fusion proteins that target and inhibit semaphoring-mediated signalling pathways to treat prostate and other cancers. The results described herein show that B1SP fusion proteins are potent inhibitors of semaphoring signalling and use in the treatment of cancer. B1SP fusion proteins bind to neuropilin and plexin in a dose dependent manner. B1SP fusion protein treatment can lead to inhibition of cell viability and induction of cell death of prostate cancer cells in a dose and concentration dependent manner. Furthermore, B1SP fusion protein is shown herein to inhibit cell adhesion in prostate cancer cells. B1SP fusion protein is shown herein to inhibit EGFR phosphorylation and R1881-induced proliferation of prostate cancer cells.

Any terms not directly defined herein shall be understood to have the meanings commonly associated with them as understood within the art of the invention. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions, devices, methods and the like of embodiments of the invention, and how to make or use them. It will be appreciated that the same thing may be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein. No significance is to be placed upon whether or not a term is elaborated or discussed herein. Some synonyms or substitutable methods, materials and the like are provided. Recital of one or a few synonyms or equivalents does not exclude use of other synonyms or equivalents, unless it is explicitly stated. Use of examples in the specification, including examples of terms, is for illustrative purposes only and does not limit the scope and meaning of the embodiments of the invention herein.

Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures. The invention is herein further described with reference to the following, non-limiting, examples. A description of the experimental procedures employed follows the examples.

Materials and Methods

B1SP binds to Plexin B1 and NRP1 in a dose dependent manner. DU145 cells were washed and treated with the indicated dose of B1SP protein for 1 hour. Cells were then washed three times with DPBS and then lysed. B1SP protein in complex with cellular proteins were isolated using protein G agarose. Protein complexes were washed three times prior to the addition of sample buffer. Samples were boiled and analyzed by Western Blot. Shown are representative Dose-Responses to B1SP treatment. Recombinant human IgGFc was used as control. Densitometry analysis of NRP1 and PLEXIN B1 in complex with B1SP fusion protein was performed using Syngene Gene Tools™ version 4.02 (Synoptics Ltd.™, Cambridge, UK). In FIGS. 3C and 3D B1SP binding to Plexin B1 and NRP1 was measured. DU145 cells were washed and treated with the indicated dose of B1SP protein for 1 hour. Cells were then washed three times with DPBS and then lysed. B1SP protein in complex with cellular proteins were isolated using protein G agarose. Protein complexes were washed three times prior to the addition of sample buffer. Samples were boiled and analyzed by Western Blot. Shown are representative Dose-Responses to B1SP treatment. Recombinant human IgGFc was used as control. The relative amount of B1SP in complex with either NRP1 or, Plexin B1 was determined from three independent experiments followed by densitometry analysis of NRP1 and PLEXIN B1 in complex with B1SP fusion protein was performed using Syngene Gene Tools™ version 4.02 (Synoptics Ltd.™, Cambridge, UK).

In FIGS. 3F, G and H, B1SP binding to PLEXINB1 was tested in DU145 cells. Photomicrographs of in-situ proximity ligation assay (PLA), showed punctate red fluorescence as an indication of protein interactions between the indicated molecules and were plotted on the Y-axis of the graphs from cells representative from 5-fields of view. PLA analysis was done by seeding 40,000 DU145 cells on 1 cm coverslips. Cells were then treated with either rhIgGFc as control or B1SP in HBHA binding buffer containing 5% BSA on ice for 1 h. The coverslips were then washed three times in HBHA buffer before PLA probe binding, ligation and amplification steps. PLA was carried out under the manufacturers protocol and analyzed using Duolink Image™ tool software. Bars represent Mean and SEM Interactions/cell. The data was statistically significant using the non-parametric Mann-Whitney statistical test as calculated in Graph Pad Prism™ software. Exact p-values are shown and the results are representative of independent repeated experiments. To distinguish between B1SP and endogenous PLEXIN B1, antibodies against the c-terminus of PLEXIN B1 were used. Mouse primary antibodies against hIgG-(Fc)-specific and Rabbit anti-human PLEXIN B1 c-terminal were used for PLA in (F). SEMA3C antibodies N20 (SantaCruz™) (Goat) and NRP1 (Rabbit) were used in (G). Anti-SEMA3C (N20) and PLEXINB1 c-terminal antibodies were used in (H).

FIGS. 4A and 4B Inhibition of EGFR phosphorylation in LNCaP. Cells were serum starved for 24 hr. B1SP conditioned medium (CM) was added for the indicated time points followed by stimulation with EGF (5.0 ng/ml) for to min. Cells were harvested and evaluated for the expression of EGFR phosphorylation (pEGFR) and total EGFR expression. The Blot was reprobed with anti-vinculin as loading control. Untreated cells were either stimulated similarly or directly lysed at the 6 hour time point as a control for comparison of EGFR phosphorylation at the end of the time course and to control for any effect incubation time may have on the capacity to stimulate EGFR phosphorylation in LNCaP. Densitometric analysis of EGFR phosphorylation levels relative to vinculin expression levels in LNCaP treated with B1SP CM over a six hour time-course. B1SP inhibits EGFR phosphorylation in a time-dependent manner. LNCaP cells were serum starved for 24 hr. Cells were then treated with B1SP as indicated for 60 minutes followed by stimulation with EGF for to min. The blot shows EGF phosphorylation. The blot was then reprobed with vinculin as loading control. Densitometric analysis of EGF phosphorylation levels.

LNCaP cells were seeded at 4×105 cells/well in 6-well plates in RPMI medium containing 10% FBS. The next day, the medium was replaced with RPMI minus phenol-red and serum starved for 24 h. The medium was changed again just prior to stimulation to remove endogenous secreted SEMA3C. For EGF stimulations, cells were first treated with B1SP at the indicated concentration for the indicated time point (A) or, for 60 min (C) followed by stimulation with EGF for to min. Cells were washed once with PBS. Cells were immediately lysed with 250 μL lysis buffer (50 mM Tris pH7.5, 150 mM NaCl, 1% NP-40, 10 mM NaF, 10% Glycerol) containing Complete and PhosStop phosphatase protease inhibitors (Roche™, Mississauga, ON). Whole cell lysates were centrifuged at 14,000 rpm for 20 min at 40 C. The protein concentration in cleared whole cell lysates was determined using the BCA kit (Thermo Scientific™, Rockville, Ill.). Protein lysates (50 μg) were analysed by SDS-PAGE (8%) and transferred by Western Blot to nitrocellulose membranes (Bio-Rad™, Hercules, Calif.). Membranes were blocked in PBS containing 5% BSA for probing with phospho-antibodies or 5% non-fat milk for total and loading control antibodies as directed by the manufacturers. Membranes were washed 3×5 min with TBST followed by incubation with the appropriate HRP or IRdye-conjugated-secondary antibodies for 1 h. Blots were washed again 3× for 5 min with TBST. Detection was by ECL or by image analysis using a LICOR infrared imager and Image Studio Lite version 3.1, software. Densitometry analysis of EGFR phosphorylation was performed using Syngene Gene Tools™ version 4.02 (Synoptics™ Ltd., Cambridge, UK).

FIG. 5A-C (A) Inhibition of EGFR phosphorylation in LNCaP. LNCaP cells were serum starved, media was then changed and the cells were treated with either truncated Semaphorin Fusion proteins (2.0 μM) (ALB SRGLI) and Plexin B1 Fusion protein (B1SP) (2.0 μM) for 60 minutes. Cells were then stimulated with EGF (10 ng/ml) for to min. Cells were harvested and evaluated for the expression of EGFR phosphorylation (pEGFR), and EGFR levels. Blots were reprobed for Vinculin as loading control. Densitometry analysis EGFR phosphorylation levels was performed using Syngene Gene Tools version 4.02 (Synoptics Ltd.™, Cambridge, UK).

As shown, the inhibitory effect of B1SP on EGFR phosphorylation was stronger than other inhibitor proteins including ALB SRGLI. (B) B1SP inhibits phosphorylation of SHC isoforms downstream of the EGFR. LNCaP cells were treated with B1SP (2.0 μM) for 60 min. The cells were then stimulated with EGF (10 ng/ml) for 10 min, washed once with PBS and lysed with NP40 lysis buffer supplemented with protease inhibitors. Whole Cell protein Lystes (30 μg) were separated by SDS PAGE and immunoblotted with anti-phospho-SHC antibodies (2434, Cell Signaling Technology™, Inc. Beverly, Mass.) and ECL detection. Total SHC levels were determined by re-probing the blot with Anti-SHC antibodies (clone 30/SHC, BD Transduction Laboratories™, Lexington, Ky.) and detection using anti-mouse, IR 680 (Rockland™, Gilbertsville, Pa.) and image analysis using LICOR infrared imaging system and Image StudioLite™ version 3.1 software.

FIGS. 6A and 6B (A) LNCaP cells were serum starved for 24 hr. Cells were treated simultaneously with B1SP and Semaphorin 3C:Fc for 60 minutes, B1SP alone, Sema3C:Fc alone or, left untreated. Cells were then stimulated with EGF (10 ng/ml) for to min. The data shows the resulting levels of EGFR phosphorylation. The blot was re-probed with vinculin as loading control. (B) Quantitative densitometric analysis of the above blot. The data demonstrates that B1SP can inhibit Sema3C-mediated EGFR phosphorylation. Densitometry analysis EGFR phosphorylation levels was performed using Syngene Gene Tools version 4.02 (Synoptics Ltd.™, Cambridge, UK). In FIG. 6C, LNCaP cells were serum starved for 24 hr. Cells were treated simultaneously with B1SP and Semaphorin 3C:Fc for 60 minutes, B1SP alone, Sema3C:Fc alone or, left untreated. Cells were then stimulated with EGF (10 ng/ml) for to min. The resulting levels of EGFR phosphorylation were measured by quantitative densitometric analysis and the blot was re-probed with vinculin as loading control. Densitometry analysis EGFR phosphorylation levels was performed using Syngene Gene Tools™ version 4.02 (Synoptics Ltd.™, Cambridge, UK).

FIGS. 7A and 7B Inhibition of EGFR phosphorylation in LNCaP and 22RV1 PC cells, respectively. Cells were serum starved B1SP CM (1.0 ml) was added to the cells at the indicated concentrations (A) and at the indicated time-points (B) followed by stimulation with 10.0 ng/ml and 5.0 ng/ml EGF for to minutes, respectively. Cells were harvested, lysed and evaluated for the expression of pEGFR, and EGFR. Blots were re-probed for Vinculin as loading control. Control EGFR phosphorylation was evaluated in untreated cells at the termination of the time course. Densitometric analysis of a dose dependent and time dependent decrease of EGFR phosphorylation in response to B1SP CM treatment of LNCaP and 22Rv1 cells, respectively. Similarly, the inhibition of EGFR phosphorylation was tested in 22RV1 PC cells (C), MCF10A normal human mammary cells (D), MR49F PC cells (E) and V16A castration-resistant prostate cancer (CRPC) stem cells (F), with increasing concentrations of B1SP (i.e. 0.5, 1, 2 and 4.0 μM).

FIG. 8A-8D B1SP inhibits PC cell proliferation in LNCaP in a dose Dependent manner with an IC50 (1.145 μM). Cell viability was measured using fluorescent-based PrestoBlue™ staining. LNCaP (3×10⁴/ml) were plated in the presence or absence of B1SP (0-2.0 μM) in 96-well flat bottom tissue culture plates. Proliferation was assessed for 4 days later in response to B1SP treatment in the presence of R1881 (nM), wherein the R1881 vehicle (ethanol) was used as control. Cell growth was assayed using the using the Presto Blue™ proliferation viability reagent as directed by the manufacturer, (Life Technologies™ Corporation, Carlsbad, Calif.).

FIGS. 9A and 9B Purified and CM B1SP molecular weight confirmation Coomassie staining of purified B1SP protein under reducing (R) and non-reducing (NR) conditions. LNCaP cells were treated for 48 hours with purified B1SP protein. Cell viability was then analyzed using a fluorescence-based live/dead cell viability assay (Calcein/Propidium Iodide). Two independent experiments are shown. Transparent Corning 96-well multiwell Plates were coated with Fibronectin from human plasma (R&D 1918FN, Sigma F2006, 5.0 μg/cm²) coat the culture surface with a minimal volume (50-75 μl), 1 h at 37 C. Allow to air dry for at least 45 minutes at room temperature. LNCaP cells were grown in media supplemented with 10% FBS and for assay were washed 3 times with serum free media and then serum starved for 8 h. Cells were detached with 10 mM EDTA in the media. Cells were washed to remove EDTA and resuspended in Dulbecco's PBS with calcium and magnesium (GIBCO™, Life Technologies™, Gaithersburg, Md., Catalog #14040-117) with 0.1% BSA at a concentration of 2.5×10⁶ cells/mL. Calcein AM (Molecular Probes™, Catalog #C3099), (12.5 μM) was added and the cells were incubated at room temperature for 30 minutes in the dark. Cells were then washed twice in PBS with calcium and magnesium and then resuspended in PBS with calcium and magnesium at a concentration of (1×10⁶ cells/ml). 100 μL of the cell suspension was added to each well in triplicate. The plates were centrifuged at 411×g for 2 minutes to move the cells to the plate surface. Plates were then incubated for 30 minutes at 37° C. and then initially measured for “before wash” fluorescence of the samples using a fluorescence plate reader at excitation wavelength 485 nm and emission wavelength 520 nm. Forty-eight hours later, plates were washed to remove non-adherent cells using the following procedure: plates were inverted and the contents of the wells was tapped out. 200 μL/well of 1×PBS was added, the plate was then rotated horizontally 180°, inverted and tapped out again and repeated a second time. 100 μL/well of 1×PBS was added to all wells. Plates were read plate “after wash” on the fluorescence plate reader. Bars represent the average percent live cells of the initial cells plated using the following formula: [(RFU after wash)/(RFU before wash)]×100.

FIGS. 10A and 10B B1SP treatment inhibits adhesion of Prostate cancer cells. LNCaP or DU145 cells were pulsed with calcein AM (12.5 μM) and incubated for 30 min. Cells (1×10⁵) were seeded on precoated, fibronectin (509 g/ml) 96-well plates and centrifuged briefly prior to incubation in the presence or absence of B1SP for 16-24 hr. Cell Fluorescence was measured before and after removal of non-adhered cells by washing. Data represents the average (%) Adhesion of triplicate wells. Transparent Corning 96-well multiwell Plates were coated with Fibronectin from human plasma (R&D 1918FN, Sigma F2006, 5.0 μg/cm²) coat the culture surface with a minimal volume (50-75 μl), 1 h at 37 C. Allow to air dry for at least 45 minutes at room temperature. LNCaP and DU145 cells were grown in media supplemented with 10% FBS and for assay were washed 3 times with serum free media and then serum starved for 8 h. Cells were detached with 10 mM EDTA in the media. Cells were washed to remove EDTA and resuspended in Dulbecco's PBS with calcium and magnesium (GIBCO™, Life Technologies™, Gaithersburg, Md., Catalog #14040-117) with 0.1% BSA at a concentration of 2.5×10⁶ cells/mL. Calcein AM (Molecular Probes™, Catalog #C3099), (12.5 μM) was added and the cells were incubated at room temperature for 30 minutes in the dark. Cells were then washed twice in PBS with calcium and magnesium and then resuspended in PBS with calcium and magnesium at a concentration of (1×10⁶ cells/ml). 100 μL of the cell suspension was added to each well in triplicate. The plates were centrifuged at 411×g for 2 minutes to move the cells to the plate surface. Plates were then incubated for 30 minutes at 37° C. and then initially measured for “before wash” fluorescence of the samples using a fluorescence plate reader at excitation wavelength 485 nm and emission wavelength 520 nm. Forty-eight hours later, plates were washed to remove non-adherent cells using the following procedure: plates were inverted and the contents of the wells was tapped out. 200 μL/well of 1×PBS was added, the plate was then rotated horizontally 180°, inverted and tapped out again and repeated a second time. 100 μL/well of 1×PBS was added to all wells. Plates were read plate “after wash” on the fluorescence plate reader. Bars represent the average and SD percent adhesion of initial cells plated using the following formula: [(RFU after wash)/(RFU before wash)]×100.

FIG. 3E Determination of B1SP EC50 (8.436 nM). PE-labelled B1SP (B1SP-PE) was serially diluted and added to DU145 cells in triplicate wells for 1 hour. Cells were washed with DPBS before measurement of PE-Fluorescence intensity (FI). DU145 cells (2×105/ml) were plated in 12-well plates. Twenty-four hours later the cells were incubated with serial diluted B1SP-PE in DPBS/20 mM HEPES in a volume of 1.0 ml. Cells were incubated at 370 C and 5% CO₂ for 60 min. Cells were then washed three times with DPBS/HEPES and then gently scraped and transferred to Flow Cytometry tubes. The cells were centrifuged at 1300 rpm for 5 minutes and finally resuspended in 0.5 ml PBS containing 2% FBS. As control, the cells were treated in parallel with rhIgGFc (100 nM) and then stained with secondary antibody, anti-IgGFc-specific conjugated to PE. The level of staining of control cells at 100 nM rhIgGFc was 6.01% whereas the level of B1SP-PE staining at 100 nM was 89.7%. The relative binding of B1SP-PE was determined by Flow Cytometry on a Bectin Dickenson FACSCantoII Flow Cytometer (BD Biosciences™, Mississauga, On).

Assessment of In Vivo Tumor Growth for Castration-Resistant C4-2 (CRPC) Xenografts.

For C4-2 castration-resistant (CRPC) xenograft model, C4-2 cells (1×10⁶) were inoculated subcutaneously in bilateral flank regions of 6-8 week-old male athymic nude mice (Harlan Sprague Dawley, Inc.™, Indianapolis, Ind.) via a 27-gauge needle under methoxyfluorane anesthesia. Body weight, tumor volume and serum PSA levels were measured once a week. Blood samples were obtained from tail vein incisions and serum PSA was determined by the Roche Diagnostics Cobas411™ immunoassay system which is an automated, random access multichannel analyzer for immunological analysis using enhanced chemiluminescent technology (ECL™). When mice bearing C-42 tumors reached a tumor volume over 200 mm³ or serum PSA reached levels greater than, 75 ng/ml, castration was performed via the scrotum under isoflurane anesthesia. Treatment commenced three times per week when PSA recovered to pre-castration levels. Tumor volume was monitored by caliper measurement and calculated by the formula length×width×depth×0.5236. Eighteen mice were randomized into 2 groups for treatment with 10 mg/Kg B1SP or PBS control. Serum PSA levels were measured once a week. Blood samples were obtained from tail vein incisions and serum PSA measured by the Roche Diagnostics Cobas411™ immunoassay system which is an automated, random access multichannel analyzer for immunological analysis using enhanced chemiluminescent technology (ECL™). When mice bearing LNCaP tumors reached a tumor volume over 200 mm³ or serum PSA levels reached greater than 75 ng/ml, castration was performed via the scrotum under isoflurane anesthesia. Treatment commenced when PSA recovered to pre-castration levels.

Plexin B1 siRNA

Plexin B1 siRNA1 was validated (Hs_PLXNB1_6, Qiagen™, Montreal,PQ) and Plexin B1 siRNA2 was previously validated by (Swiercz et al., 2008) and was synthesized (ThermoScientific™, Rockford, Ill.). LNCaP cells were transfected with either scramble siRNA (AUCAAACUGUUGUCAGCGCUGUU) (SEQ ID NO: 7), PlexinB1siRNA1 (CCGGGUGGAAUUUAUCCUUGAUU) (SEQ ID NO: 8), or, Plexin B1siRNA2 (ACCACGGUCACCCGGAUUCUU) (SEQ ID NO: 9), (10 nM) using HiPerFect™ reagent (Qiagen™, Montreal PQ) as described by the manufactuer. Transfected cells were incubated for 72 hours and then incubated in the presence or absence of SEMA3C:Fc (100 nM) for 10 minutes. Cells were washed and then lysed. Plexin B1 levels were analyzed from lysates (30 μg) by polyacrylamide gel electrophoresis (PAGE). Western Blots were probed with anti-Plexin B1 and anti-phospho-Shc.

Blots were re-probed with anti-vinculin and anti-Shc as loading control. DU145 cells were transfected with scramble siRNA, Plexin B1siRNA1 or PlexinB1 siRNA2 (10 nM) using RNAiMax™ reagent as directed by the manufacturer, (Invitrogen™, Missisauga, Ontario). Following 72 hours incubation the cells were replated at 20,000 cells/well in a 96-well flat bottom plate and let adhere for 4 hours. The remaining cells were lysed and assayed for PlexinB1 expression by Western Blot. The blot was reprobed with vinculin as loading control. Medium was replaced with DMEM without serum for 16 hours prior to the binding assay. Cells were then washed once with HBHA [20 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 1 mM MgCl2], buffer containing, 0.5% BSA. The Opti-MEM1-conditioned medium from 293T cells expressing either the APTag vector alone or, the AP-SEMA 3C construct was assayed in a PNPP assay to find the linear and equivalent range of AP-enzymatic activity. The AP-SEMA3C was applied by diluting an equal volume of AP-SEMA3C CM to an equal volume of HBHA buffer that gave an enzymatic activity of 0.877. The APTag was first diluted 1:4 in Opti-MEM and then an equal volume of the 1:4 diluted—APTag CM was diluted to an equal volume of HBHA. The enzymatic activity of AP-Tag CM was 1.069.

The binding assay was performed as previously described by FLANAGAN, J G. and LEDER, P. (1990), endogenous phosphatase heat inactivation was done in HBHA at 65° C. following the fixation step. Plate readings at 562 nm were taken initially and then every 24 hours. The data was done in quadruplet. The binding of the APTag vector CM was subtracted from the binding to APSEMA3C in each case.

Apoptosis Assay

In FIG. 13, LNCaP and C4-2 cells (2.5×104) were plated in 6-well plates for twenty-four hrs when the medium was replaced with RPMI in the absence of Phenol red or serum. B1SP at the indicated concentrations was added and the cells were incubated at 37° C. and 5% CO2 for 4 days. The cells were harvested from medium and adherent cells by gentle scraping. The cells were then centrifuged at 1300 rpm, washed once in PBS and lysed with 200 μl NP40 lysis buffer containing protease inhibitors. Samples (30 μg) were separated by SDS PAGE. The gel was immunoblotted with Total PARP and Cleaved PARP (9542, 9541, Cell Signaling Technologies Inc.™, Beverly, Mass.). The blot was re-probed with anti-Actin to demonstrate equal loading of protein lysates.

In FIG. 14, PLA analysis was performed as previously described using the Duolink™ in-situ PLA kit (Sigma-Aldrich™, Oakville, ON), where C-terminal anti-PLEXIN B1 was used to distinguish the endogenous PLEXIN B1 and B1SP and Mouse Anti-HER2 were used.

EXAMPLES

The following working examples are provided for illustrative purposes, and are not intended to be limiting, as such.

Example 1A: A B1SP Fusion Protein Binds NRP1 and Plexin B1 in a Dose Dependent Manner

Semaphorins and their receptors (mainly plexins and neuropilins) are aberrantly expressed in human tumors. Semaphorin 3C binding and signaling requires the interaction of neuropilin1 or 2, co-receptors for Plexin B1. A B1SP fusion protein has potential to inhibit Semaphorin signaling by competing for Semaphorin binding to neuropilin and thereby inhibiting signaling via Plexin B1. As shown in FIGS. 3A and 3B a B1SP fusion protein co-immunoprecipitates with NRP1 and Plexin B1 in a dose dependent manner. FIGS. 3C and 3D show B1SP binding to Plexin B1 and NRP1 in a dose dependent manner. The bar graphs represent the relative amount of B1SP in complex with either NRP1 or, Plexin B1 obtained from three independent Western blotting experiments followed by densitometry analysis of NRP1 and PLEXIN B1 in complex with B1SP fusion protein was performed.

Example 1B: Plexin B1 Silencing Inhibits SEMA3C Signaling

DU145 cells transfected with scramble siRNA or, two distinct siRNAs targeting Plexin B1. Inhibition of Plexin B1 protein levels following 72 hr incubation from whole cell lysates and Western Blot analysis probed with Plexin B1 antibodies (data not shown). The blot was then probed with anti-Vinculin to demonstrate equal loading of protein lysates. AP-Sema3C binding to DU145 cells that were transfected with scramble or Plexin B1 siRNAs, where the mean and SEM AP-Sema3C binding performed was calculated in quadruplicate. Knockdown of Plexin B1 resulted in a reduced binding of AP-Sema3C by 2.4-fold with Plexin siRNA1 and 1.9-fold with Plexin B1 siRNA2 compared to control scramble siRNA. There was also a decrease in Sema3C-mediated SHC phosphorylation in response to silencing of Plexin B1. LNCaP cells were transfected with scramble or, Plexin B1 siRNAs and then incubated for 72 hours. Cells were serum starved for 16 hr and then incubated in the presence or absence of SEMA 3C (100 nM) for 10 minutes. Western Blots were probed with Plexin B1 antibodies to demonstrate specific inhibition of Plexin B1 and anti-phospho-SHC. Blots were re-probed anti-SHC and anti-Vinculin as loading controls (data not shown).

Example IC: B1SP Enhances PLEXIN B1 and HER2/ErbB2 Interaction

Surprisingly, the addition of B1SP enhances the interaction of PLEXIN B1 with HER2/ErbB2 in DU145 cells (i.e. based on U.S. Pat. No. 9,198,966), as shown in FIG. 14.

Example 2: A B1SP Fusion Protein Inhibits EGFR Phosphorylation

FIG. 4 shows inhibition of EGFR phosphorylation in LNCaP cells. The LNCaP cells were serum starved for 24 hrs. before a B1SP fusion protein conditioned medium (CM) was added 2, 4 and 6 hour time points followed by stimulation with EGF (5.0 ng/ml) for to min. The cells were harvested and evaluated for the expression of EGFR phosphorylation (pEGFR) and total EGFR expression. The blots were reprobed with anti-vinculin as loading control. Untreated cells were either stimulated similarly or directly lysed at the 6 hour time point as a controls for comparison of EGFR phosphorylation at the end of the time course and to control for any effect incubation time may have on the capacity to stimulate EGFR phosphorylation in LNCaP.

FIG. 5A also shows inhibition of EGFR phosphorylation in LNCaP cells. LNCaP cells were serum starved, media was then changed and the cells were treated with either truncated Semaphorin Fusion proteins (2.0 μM) (ALB SRGLI) and Plexin B1 Fusion protein (B1SP fusion protein) (2.0 μM) for 60 minutes. The cells were then stimulated with EGF (10 ng/ml) for 10 min before the cells were harvested and evaluated for the expression of EGFR phosphorylation (pEGFR), and EGFR levels. Blots were then reprobed for vinculin as loading control. The inhibitory effect of a B1SP fusion protein on EGFR phosphorylation was stronger than other inhibitor proteins including ALB. Furthermore, an alternative c-terminal Albumin fusion (SDPSI-L-ALB) was tested (data not shown). SDPSI-L-ALB showed activity identical to the n-terminal Albumin fusion (ALB-L-SDPSI or ALB SRGLI).

FIGS. 5B and C show that a B1SP fusion protein inhibits phosphorylation of She isoforms downstream of the EGFR.

FIG. 6A shows LNCaP cells that were serum starved for 24 hrs. before the cells were treated simultaneously with a B1SP fusion protein and Semaphorin 3C:Fc for 60 minutes, B1SP alone, Sema3C:Fc alone or, left untreated. The cells were then stimulated with EGF (10 ng/ml) for to min. The blot was re-probed with vinculin as loading control. FIG. 6B shows quantitative densitometric analysis of the blot of FIG. 6A. The data demonstrates that B1SP can inhibit Sema3C-mediated EGFR phosphorylation. The data shows the resulting levels of EGFR phosphorylation. Similarly, FIG. 3C demonstrates that B1SP can inhibit Sema3C-mediated EGFR phosphorylation and is not inhibited by SEMA3C:Fc alone.

FIG. 7 also shows inhibition of EGFR phosphorylation in LNCaP and 22RV1 PC cells. The cells were serum starved before a B1SP fusion protein conditioned medium (CM) was added to the cells at the indicated concentrations (i.e. 0.5, 1, 2 and 4 μM—A) and for the indicated time-points (i.e. 1, 2 and 4 hrs.—B) followed by stimulation with 5.0 ng/ml EGF for 10 minutes. The cells were harvested and evaluated for the expression of pEGFR, and EGFR. The blots were re-probed for vinculin as a loading control. Control EGFR phosphorylation was evaluated in untreated cells at the termination of the time course. FIGS. 7A and 7B show plots of a quantitative densitometric analysis. Similarly, the inhibition of EGFR phosphorylation was also tested in 22RV1 PC cells (C), MCF10A normal human mammary cells (D), MR49F PC cells (E) and V16A castration-resistant prostate cancer (CRPC) stem cells (F), with increasing concentrations of B1SP (i.e. 0.5, 1, 2 and 4.0 μM) and showed a similar decline in EGFR phosphorylation.

B1SP inhibition of SEMA3C-mediated EGFR phosphorylation was also seen in U87MG glioblastoma cells, which were seeded at 2.5×105 cells in 6-well dishes and incubated overnight. The medium was then replaced with RPM1 without serum and Phenol red and incubated for 24 h. The cells were then treated with PBS as control or B1SP (2 μM) for 1 hour. The cells were then either stimulated with SEMA3C:Fc (1 μM) or PBS control for 20 minutes at 370 C and 5% CO2. Cells were processed for immunoblotting as previously described (immunoblot not shown). Additionally, dosage dependent inhibition of HGF-mediated MET and MAPK phosphorylation in serum-starved T24 Bladder cancer cells treated for 3 h with B1SP (0-4 μM) or PBS control was also tested. Cells were stimulated as indicated with HGF (1 nM) for 20 min followed by a wash in cold PBS and lysis in NP40 lysis buffer. The immunoblot showed the relative MET and MAPK phosphorylation decreased as the concentration of B1SP increased. Immunoblots were re-probed with MET and MAPK antibodies and Vinculin as loading controls (immunoblot not shown).

Example 3: B1SP Fusion Protein Inhibits LNCaP Cell Proliferation

In (A), cells were treated with synthetic androgen (R1881) as indicated and cell proliferation was evaluated using the PrestoBlue proliferation assay over a period of 5 days. In (B), LNCaP cells were treated with R1881 (nM) in combination with increasing concentration B1SP and cell proliferation was monitored over a period of 4 days. In (C), the inhibitory effect of B1SP on growth expressed as percentage of maximum androgen (R1881) sensitive growth.

FIG. 8A shows fluorescence intensity (FI) as a representation of cell proliferation over a 4 day period for a B1SP fusion protein at 2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.125 μM and 0 μM. Similarly, FIG. 8B shows fluorescence intensity (FI) as a representation of cell proliferation over a 4 day period in LNCaP cells treated with R1881 (mM) and B1SP fusion protein at 2 μM, 1 μM and 0 μM, with EtOH control. FIG. 8D shows a plot of B1SP fusion protein dose response on a log scale.

Example 4: A B1SP Fusion Protein Increases LNCaP Cell Death

Purified and CM B1SP molecular weight was confirmed by Coomassie staining of purified B1SP protein under reducing (R) and non-reducing (NR) conditions (data not shown). Coomassie blue staining for a B1SP fusion protein showed a 97 kDa monomer (R) and 193 kDa dimer (NR). Similarly, conditioned medium harvested from CHO cells secreting a B1SP fusion protein was evaluated by Western blot with N-terminal, anti-Plexin B1 antibodies (data not shown).

As shown in FIGS. 9A and 9B, LNCaP cells were treated for 48 hours with purified a B1SP fusion protein and cell viability was then analyzed using a fluorescence-based live/dead cell viability assay (Calcein/Propidium Iodide). FIGS. 9A and 9B show two independent experiments.

Example 5: A B1SP Fusion Protein Inhibits Adhesion of Prostate Cancer Cells (LNCaP and DU145) to Fibronectin

As shown in FIGS. 10A and 10B, a B1SP fusion protein treatment inhibits adhesion of prostate cancer cells (i.e. LNCaP or DU145 cells). The cells were pulsed with calcein AM (12.5 μM) and incubated for 30 min. The cells (1×10⁵) were seeded on precoated fibronectin (50 μg/ml) 96-well plates and centrifuged briefly prior to incubation in the presence or absence of a B1SP fusion protein for 16-24 hr. Cell Fluorescence was measured before and after removal of non-adhered cells by washing. Data represents the average (%) Adhesion of triplicate wells.

Example 6: A B1SP Fusion Protein Inhibits R1881-Induced Proliferation of LNCaP Cells in a Dose Dependent Manner

FIGS. 11A-C shows a B1SP fusion protein inhibits proliferation of androgen sensitive LNCaP cells. A Cells were treated with synthetic androgen (R1881) as indicated. Cell proliferation was evaluated using the PrestoBlue proliferation assay over a period of 5 days. B LNCaP cells were treated with R1881 (1 nM) in combination with increasing concentration B1SP. Cell proliferation was monitored over a period of 4 days. C Represents the inhibitory effect of a B1SP fusion protein on growth expressed as percentage of maximum androgen (R1881) sensitive growth.

Example 7: In Vivo Assay

Athymic nu^−/− mice bearing castrate resistant C4-2 xenografts were castrated and treated twice per week with 20 mg/kg B1SP or PBS control. Treatment with B1SP fusion protein suppressed C4-2 tumor growth (FIG. 11A) and serum PSA progression (FIG. 11B). FIG. 12 shows the change in serum PSA levels from Day 7 to Day 14 of individual castrate resistant C4-2 xenograft bearing mice (CRPC) treated with (A) PBS control (n=9) or (B) B1SP (n=7). FIG. 13 shows that treatment of LNCaP and C4-2 cells with B1SP fusion protein induces apoptosis in a dose dependent manner as monitored by immunoblot analysis for PARP cleavage.

Example 8: IC₅₀ Values for Various Cancer Cell-lines Tested for B1SP-mediated Proliferation Sensitivity

A variety of cancer cell lines were tested for B1SP-mediated proliferation sensitivity to calculate the IC₅₀ value for each cell type as a representation of B1SP's effectiveness in the treatment of the cancer type. Inhibition of LNCaP, C42, MR49F, U87MG, Caki-1, Caki-2 and T24 cells were tested for proliferation in response to increasing doses of B1SP (i.e. 2, 1, 0.5, 0.25 and 0.125 μM) as compared to PBS controls. LNCaP cells were also administered R1881 as described above and used a EtOH and PBS control. Day 4 data were normalized to day 0 using GraphPad prism software. C4-2 are CRPC cells, MR49F cells are Enzalutamide-dependent (10 μM) LNCaP-derivative cells, U87MG are glioblastoma cells, Caki-1 and Caki-2 are renal carcinoma cells and T24 are bladder cancer cells.

TABLE 2 below summarizes the IC₅₀ values of the various cancer cell-lines tested for B1SP-mediated proliferation sensitivity.

TABLE 2
IC50 Values by Cell Line and Cancer Type
	Type of Cancer	Cell Line	IC50 (μM)
	Prostate	LNCap	0.2509
		C42	0.9636
		MR49F	0.981
	Glioblastoma	U87MG	2.965
	Kidney	Caki-1	2.215
		Caki-2	0.1725
	Bladder	T24	0.06164

Example 9: Expression of SEMA Peptides with More than One PSI Domain

B1SP and B1R4 were expressed in HEK 293T cells but only B1SP was secreted into the conditioned medium. HEK 293T cells were transfected with B1SP and B1R4 expression clones. Twenty four hours later the medium was replaced with Opti-Mem and incubated at 37° C. in 5% CO₂ for an additional 48 h. Conditioned medium was harvested, concentrated and analysed by immunoblotting using anti-Plexin B1 for whole cell lysates (WCL) and HRP conjugated anti-Fc antibodies for conditioned medium (CM). It is suspected that the B1R4 secretion was inhibited by the additional PSI domains (i.e. B1SP has only one PSI domain).

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. The word “comprising” is used herein as an open-ended term, substantially equivalent to the phrase “including, but not limited to”, and the word “comprises” has a corresponding meaning. As used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a thing” includes more than one such thing. Citation of references herein is not an admission that such references are prior art to the present invention.

REFERENCES

• BALLARD et al 1998 Infect. Immun 66:615-619.
• BLANKE et al 1996 Proc Natl Acad Sci 93: 8437-8442.
• BRUCHOVSKY, N., P. RENNIE, et al. (1988). Mechanisms and effects of androgen withdrawal therapies. Prostatic Cancer: Rationale of endocrine management. Berlin, Walter De Gruyer & Co.: 3-14.
• BRUCHOVSKY, N., P. S. RENNIE, et al. (1989). Limitations of androgen withdrawal therapy of prostatic carcinoma—the next step? Prostate Cancer-The Second Tokyo Symposium. New York, Elsevier: 1-10.
• DEMARCHI et al 1996 J Virol 70:4427-4437.
• DIETZ et al 2004. Mol Cell. Neurosci 27:85-131.
• DILBER et al 1999 Gene Ther. 6:12-21.
• FUJIHARA et al 1999 EMBO J 18:411-419.
• GHERARDI E. et al. Current Opinion in Structural Biology (2004) 14:669-678.
• GIORDANO, S., S. CORSO, et al. (2002). “The semaphorin 4D receptor controls invasive growth by coupling with Met.” Nat Cell Biol 4(9): 720-4.
• GOLDENBERG, S. L., N. BRUCHOVSKY, et al. (1988). “The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.” J Urol 140(6): 1460-5.
• HARITON-GAZAL et al 2002 Biochemistry 41:9208-9214.
• HEINLEIN, C. A. and CHANG C. (2004), “Androgen Receptor in Prostate Cancer.” Endocrine Reviews 25(2): 276-308.
• HERMAN, J. G. and G. G. MEADOWS (2007). “Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells.” Int J Oncol 30(5): 1231-8.
• HUGGINS, C. and C. HODGES (1941). “Studies on prostatic cancer. I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate.” Cancer Res 1: 293-297.
• HUTT M. et al. The Journal of Biological Chemistry (2012) 287(7):4462-4469.
• ISAACS, J., O. CUSSENOT, et al. (1997). “Growth regulation of normal and malignant prostatic cells.” First International Consultation on Prostate Cancer: 31-87.
• KOLODKIN, A. L., D. J. MATTHES, et al. (1993). “The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules.” Cell 75(7): 1389-99.
• KRUGER, R. P., J. AURANDT, et al. (2005). “Semaphorins command cells to move.” Nat Rev Mol Cell Biol 6(10): 789-800.
• FLANAGAN, J G. and LEDER, P. (1990) “The kit ligand: a cell surface molecule altered in steel mutant fibroblasts” Cell Vol. 63(1):185-194.
• MORRIS et al 2001 Nature Biotechnol 19:1173-1176.
• NAIR et. al. 2003 J. Immunol. 170:1362-1373.
• NEGISHI, M., I. OINUMA, and H. KATOH (2005). Plexins: axon guidance and signal transduction. Cell Mol Life Sci 62:1363-1371.
• PEREZ et al 1992 J. Cell Sci 1002:717-722.
• PETRYLAK, D. P., C. M. TANGEN, et al. (2004). “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.” N Engl J Med 351(15): 1513-20.
• POOGA et al 1998 FASEB J 12: 67-77.
• PRIOR et al 1992 Biochemistry 31:3555-3559.
• RATTAN et al. (1992), Protein Synthesis: Posttranslational Modifications and Aging, “Ann NY Acad Sci 663: 48-62.
• RYSER et al 1980 Cancer 45:1207-1211.
• SEIFTER et al., Analysis for protein modifications and nonprotein cofactors, Meth. Enzymol. (1990) 182: 626-646
• SHEN et al 1978 Proc Natl Acad Sci 75:1872-1876.
• SWIERCZ, J. M., R. KUNER, et al. (2004). “Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2.” J Cell Biol 165(6): 869-80.
• SWIERCZ, J. M., T. WORZFELD, et al. (2008). “ErbB-2 and met reciprocally regulate cellular signaling via plexin-B1.” J Biol Chem 283(4): 1893-901.
• STENMARK et al 1991 J Cell Biol 113:1025-1032.
• TAMAGNONE, L. and P. M. COMOGLIO (2000). “Signalling by semaphorin receptors: cell guidance and beyond.” Trends Cell Biol 10(9): 377-83.
• TANNOCK, I. F., R. de WIT, et al. (2004). “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.” N Engl J Med 351(15): 1502-12.
• VERRAS, M., J. LEE, et al. (2007). “The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.” Cancer Res 67(3): 967-75.
• WIEDLOCHA et al 1994 Cell 76:1039-1051.
• WOLFERT et al 1996 Gene Ther. 3:269-273.
• Proteins-Structure and Molecular Properties, 2^nd ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993.
• WOLD F, Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in Posttranslational Covalent Modification of Proteins, B. C. Johnson, ed., Academic Press, New York, 1983.
• ALTSCHUL et al. 1990, J Mol. Biol. 215: 403-410.
• ALTSCHUL et al. (1997), Nucleic Acids Res. 25: 3389-3402.
• KYTE & DOOLITTLE 1982. J Mol Biol 157:105-132.
• SAMBROOK J. AND RUSSELL D. (2000) Molecular Cloning: A Laboratory Manual (Third Edition) Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
• AUSUBEL et al. (Current Protocols in Molecular Biology, John Wiley & Sons, 1994).
• “Remington's Pharmaceutical Sciences”, (19th edition), ed. A. Gennaro, 1995, Mack Publishing Company, Easton, Pa.
• “The Pharmacological basis of therapeutics”, 10^th edition. HARDMAN H G., LIMBIRD L E. editors.
• “Clinical Oncology”, 3^rd edition. Churchill Livingstone/Elsevier Press, 2004. ABELOFF, M D. editor.

INFORMAL SEQUENCE LISTING
SEQ ID NO: 1
SCAQHLDCAS CLAHRDPYCG WCVLLGRCSR RSECSRGQGP EQ
(B1SP FUSION-molecular weight homodimer 168kD Amino Acid sequence)
SEQ ID NO: 2
MPALGPALLQALWAGWVLTLQPLPPTAFTPNGTYLQHLARDPTSGTLYLGATNFLFQLSPGLQLEATV
STGPVLDSRDCLPPVMPDECPQAQPTNNPNQLLLVSPGALVVCGSVHQGVCEQRRLGQLEQLLLRPER
PGDTQYVAANDPAVSTVGLVAQGLAGEPLLFVGRGYTSRGVGGGIPPITTRALWPPDPQAAFSYEETA
KLAVGRLSEYSHHFVSAFARGASAYFLFLRRDLQAQSRAFRAYVSRVCLRDQHYYSYVELPLACEGGR
YGLIQAAAVATSREVAHGEVLFAAFSSAAPPTVGRPPSAAAGASGASALCAFPLDEVDRLANRTRDAC
YTREGRAEDGTEVAYIEYDVNSDCAQLPVDTLDAYPCGSDHTPSPMASRVPLEATPILEWPGIQLTAV
AVTMEDGHTIAFLGDSQGQLHRVYLGPGSDGHPYSTQSIQQGSAVSRDLTFDGTFEHLYVMTQSTLLK
VPVASCAQHLDCASCLAHRDPYCGWCVLLGRCSRRSECSRGQGPEQWLWSFQPELGCLGSGGGSGGGG
SEMA DOMAIN-no annotation
structural stabilization domain (PSI=plexin-semaphorin-integrin
domain)
linker
Hinge
(B1SP FUSION-nucleic acid sequence encoding fusion protein of SEQ ID
NO: 2)
SEQ ID NO: 3
atgcctgctctgggcccagctcttctccaggctctctgggccgggtgggtcctcaccctccagcccct
tccaccaactgcattcactcccaatggcacgtatctgcagcacctggcaagggaccccacctcaggca
ccctctacctgggggctaccaacttcctgttccagctgagccctgggctgcagctggaggccacagtg
tccaccggccctgtgctagacagcagggactgcctgccacctgtgatgcctgatgagtgcccccaggc
ccagcctaccaacaacccgaatcagctgctcctggtgagcccaggggccctggtggtatgcgggagcg
tgcaccagggggtctgtgaacagcggcgcctggggcagctcgagcagctgctgctgcggccagagcgg
cctggggacacacaatatgtggctgccaatgatcctgcggtcagcacggtggggctggtagcccaggg
cttggcaggggagcccctcctgtttgtggggcgaggatacaccagcaggggtgtggggggtggcattc
cacccatcacaacccgggccctgtggccgcccgacccccaagctgccttctcctatgaggagacagcc
aagctggcagtgggccgcctctccgagtacagccaccacttcgtgagtgcctttgcacgtggggccag
cgcctacttcctgttcctgcggcgggacctgcaggctcagtctagagcttttcgtgcctatgtatctc
gagtgtgtctccgggaccagcactactactcctatgtggagttgcctctggcctgcgaaggtggccgc
tacgggctgatccaggctgcagctgtggccacgtccagggaggtggcgcatggggaggtgctctttgc
agctttctcctcggctgcaccccccactgtgggccggcccccatcggcggctgctggggcatctggag
cctctgccctctgtgccttccccctggatgaggtggaccggcttgctaatcgcacgcgagatgcctgc
tacacccgggagggtcgtgctgaggatgggaccgaggtggcctacatcgagtatgatgtcaattctga
ctgtgcacagctgccagtggacaccctggatgcttatccctgtggctcagaccacacgcccagcccca
tggccagccgggtcccgctggaagccacaccaattctggagtggccagggattcagctaacagctgtg
gcagtcaccatggaagatggacacaccatcgctttcctgggtgatagtcaagggcagctgcacagggt
ctacttgggcccagggagcgatggccacccatactccacacagagcatccagcaggggtctgcagtga
gcagagacctcacctttgatgggacctttgagcacctgtatgtcatgacccagagcacactctgaag
gttcctgtggcttcctgtgctcagcacctggactgtgcatcttgccttgctcacagggacccatactg
tgggtggtgcgtgctccttggcaggtgcagtcgccgttctgagtgctcgaggggccagggcccagagc
agtggctatggagcttccagcctgagctgggctgtctgggatccggtggcggttccggtggtggaggc
ggaagcggcggtggaggatcaGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGG
GGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACCAACTGATGATCTCCCGGACCCCTGAGG
TCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGC
GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAG
CGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG
CCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTT
CTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC
CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGG
CAGCAGGGGAACGTCTTCTCATGCTCCGTGCTGCATGAGGCTCTGCACAACCACTACACGCAGAAGAG
CCTCTCCCTGTCTCCGGGTAAATGA
(ALB-L-SDPSI or ALB SRGLI) has albumin at the N-terminus fused to
linker then to SEMA3C sema domain then to psi truncated at the
natural cleavage of the furin site
SEQ ID NO: 4
MAFRTICVLVGVFICSICVKHHHHHHHHMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGE
ENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAP
ELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLS
QRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSH
CIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRIAKTYETT
LEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLV
EVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALE
VDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCK
ADDKETCFAEEGKKLVAASQAALGLGSGGGSGGGGGSGGGGSGSSQPQARVYLTFDELRETKTSEYFS
LSHHPLDYRILLMDEDQDRIYVGSKDHILSLNINNISQEALSVFWPASTIKVEECKMAGKDPTHGCGN
FVRVIQTFNRTHLYVCGSGAFSPVCTYLNRGRRSEDQVFMIDSKCESGKGRCSFNPNVNTVSVMINEE
LFSGMYIDFMGTDAAIFRSLTKRNAVRTDQHNSKWLSEPMFVDAHVIPDGTDPNDAKVYFFFKEKLTD
NNRSTKQIHSMIARICPNDTGGLRSLVNKWTTFLKARLVCSVTDEDGPETHFDELEDVFLLETDNPRT
TLVYGIFTTSSSVFKGSAVCVYHLSDIQTVFNGPFAHKEGPNHQLISYQGRIPYPRPGTCPGGAFTPN
MRTTKEFPDDVVTFIRNHPLMYNSIYPIHKRPLIVRIGTDYKYTKIAVDRVNAADGRYHVLFLGTDRG
TVQKVVVLPTNNSVSGELILEELEVFKNHAPITTMKISSKKQQLYVSSNEGVSQVSLHRCHIYGTACA
DCCLARDPYCAWDGHSCSRFYPTGKR
(SDPSI-L-ALB) has the SEMA3C sema domain and psi domain cleaved at
the furin cleavage site fused to GS linker then tc albumin
SEQ ID NO: 5
MAFRTICVLVGVFICSICVKGSSQPQARVYLTFDELRETKTSEYFSLSHHPLKYRILLMDFDQDRIYV
GSKDHILSLNINNISQEALSVFWPASTIKVEECKMAGKDPTHGCGNFVRVIQTFNRTHLYVCGSGAFS
PVCTYLNRGRRSEDQVFMIDSKCESGKGRCSFNPNVNTVSVMINEELFSGMYIDFMGTDAAIFRSLTK
RNAVRTDQHNSKWLSEPMFVDAHVIPDGTDPNDAKVYFFFKEKLTDNNRSTKQIHSMIARICPNDTGG
LRSLVNKWTTFLKARLVCSVTDEDGPETHFDELEDVFLLETDNPRTTLVYGIFTTSSSVFKGSAVCVY
HLSDIQTVFNGPFAHKEGPNHQLISYQGRIPYPRPGTCPGGAFTPNMRTTKEFPDDVVTFIRNHPLMY
NSIYPIHKRPLIVRIGTDYKYTKIAVDRVNAADGRYHVLFLGTDRGTVQKVVVLPTNNSVSGELILEE
LEVFKNHAPITTMKISSKKQQLYVSSNEGVSQVSLHRCHIYGTACADCCLARDPYCAWDGHSCSRFYP
TGKGSGGGSGGGGGSGGGGSDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLV
RPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDE
LRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLE
CADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYA
EAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLI
KQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIK
KQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGLHHHHHHH
H*
SEMA3C:FC full length SEMA3C with mutations in two furin
Semaphorin 3C amino acids 1-20 encodes signal peptide;
(human SEMA3C Gly21-Ser738: Arg551Ala, Arg552Ala, Arg611Ala,
Arg612Ala); IEGRMD linker peptide sequence; Human IgG1 (Pro100-
Lys330) and linker DKTHTCPPCP.
SEQ ID NO: 6
MAFRTICVLVGVFICSICVKGSSQPQARVYLTFDELRETKTSEYFSLSHHPLKYRILLMDIDQDRIYV
GSKDHILSLNINNISQEALSVFWPASTIKVEECKMAGKDPTHGCGNFVRVIQTFNRTHLYVCGSGAFS
PVCTYLNRGRRSEDQVFMIDSKCESGKGRCSFNPNVNTVSVMINEELFSGMYIDFMGTDAAIFRSLTK
RNAVRTDQHNSKWLSEPMFVDAHVIPDGTDPNDAKVYFFFKEKLTDNNRSTKQIHSMIARICPNDTGG
LRSLVNKWTTFLKARLVCSVTDEDGPETHFDELEDVFLLETDNPRTTLVYGIFTTSSSVFKGSAVCVY
HLSDIQTVFNGPFAHKEGPNHQLISYQGRIPYPRPGTCPGGAFTPNMRTTKEFPDDVVTFIRNHPLMY
NSIYPIHKRPLIVRIGTDYKYTKIAVDRVNAADGRYHVLFLGTDRGTVQKVVVLPTNNSVSGELILEE
LEVFKNHAPITTMKISSKKQQLYVSSNEGVSQVSLHRCHIYGTACADCCLARDPYCAWDGHSCSRFYP
TGKRRSAAQDVRHGNPLTQCRGFNLKAYRNAAEIVQYGVKNNTTFLECAPKSPQASIKWLLQKDKDAA
KEVKLNERIIATSQGLLIRSVQGSDQGLYHCIATENSFKQTIAKINFKVLDSEMVAVVTDKWSPWTWA
SSVRALPFHPKDIMGAFSHSEMQMINQYCKDTRQQHQQGDESQKMRGDYGKLKALINSIEGRMDPKSC
(scramble siRNA)
SEQ ID NO: 7
AUCAAACUGUUGUCAGCGCUGUU
(PlexinB1siRNA1)
SEQ ID NO: 8
CCGGGUGGAAUUUAUCCUUGAUU
(Plexin B1siRNA2)
SEQ ID NO: 9
ACCACGGUCACCCGGAUUCUU
B1R4
SEQ ID NO: 10
MPALGPALLQALWAGWVLTLQPLPPTAFTPNGTYLQHLARDPTSGTLYLGATNFLFQLSPGLQLEATV
STGPVLDSRDCLPPVMPDECPQAQPTNNPNQLLLVSPGALVVCGSVHQGVCEQRRLGQLEQLLLRPER
PGDTQYVAANDPAVSTVGLVAQGLAGEPLLFVGRGYTSRGVGGGIPPITTRALWPPDPQAAFSYEETA
KLAVGRLSEYSHHFVSAFARGASAYFLFLRRDLQAQSRAFRAYVSRVCLRDQHYYSYVELPLACEGGR
YGLIQAAAVATSREVAHGEVLFAAFSSAAPPTVGRPPSAAAGASGASALCAFPLDEVDRLANRTRDAC
YTREGRAEDGTEVAYIEYDVNSDCAQLPVDTLDAYPCGSDHTPSPMASRVPLEATPILEWPGIQLTAV
AVTMEDGHTIAFLGDSQGQLHRVYLGPGSDGHPYSTQSIQQGSAVSRDLTFDGTFEHLYVMTQSTLLK
VPVASCAQHLDCASCLAHRDPYCGWCVLLGRCSRRSECSRGQGPEQWLWSFQPELGCLQVAAMSPANI
SREETREVFLSVPDLPPLWPGESYSCHFGEHQSPALLTGSGVMCPSPDPSEAPVLPRGADYVSVSVEL
RFGAVVIAKTSLSFYDCVAVTELRPSAQCQACVSSRWGCNWCVWQHLCTHKASCDAGPMVASHQSPLV
SPDPPARGGPSPSPPTAPKALATPAPDTLPVEPGAPSTATASDISPGASPSLLSPWGPWAGSGSISSP
GSTGSPLHEEPSPPSPQNGPGTAVPAPTDFRPSATPEDLLASPLSPSEVAAVPPADPGPEALHPTVPL
DLPPATVPATTFPGAMGSVKPALDWLTREGGELPEADEWTGGDAPAFSTSTLLSGDGDSAELEGPPAP
LILPSSLDYQYDTPGLWELEEATLGASSCPCVESVQGSTLMPVHVEREIRLLGRNLHLFQDGPGDNEC
VMELEGLEVVVEARVECEPPPDTQCHVTCQQHQLSYEALQPELRVGLFLRRAGRLRVDSAEGLHVVLY
DCSVGHGDCSRCQTAMPQYGCVWCEGERPRCVTREACGEAEAVATQCPAPLIHSVEPLTGPVDGGTRV
TIRGSNLGQHVQDVLGMVTVAGVPCAVDAQEYEVSSSLVCITGASGEEVAGATAVEVPGRGRGVSEHD
FAYQDPKVHSIFPARGPRAGGTRLTLNGSKLLTGRLEDIRVVVGDQPCHLLPEQQSEQLRCETSPRPT
PATLPVAVWFGATERRLQRGQFKYTLDPNITSAGPTKSFLSGGREICVRGQNLDVVQTPRIRVTVVSR
MLWPSQGLGGSGGGSGGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDQLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGK*

Claims

1. A fusion protein comprising: (a) a SEMA3C sema domain or Plexin B 1 sema domain;(b) a single Plexins-Semaphorins-Integrins domain (PSI domain); and(c) a half life extending moiety, provided that when the sema domain is from SEMA3C then the half-life extending moiety is albumin and provided that when the sema domain is from Plexin B 1 then the half-life extending moiety is a fragment crystallizable region (Fc region) and the Fc region forms a dimer,provided that when the sema domain is from SEMA3C the fusion protein lacks an immunoglobulin-like domain.

2. The fusion protein of claim 1, wherein the fusion protein further comprises one or more of a linker and a hinge between the PSI domain and the half life extending moiety.

3. The fusion protein of claim 1, wherein the single PSI domain comprises the amino acid sequence SCAQHLDCASCLAHRDPYCG WCVLLGRCSRRSECSRGQGPEQ (SEQ ID NO: 1).

4. The fusion protein of claim 1, wherein the fusion protein has an amino acid sequence comprising SEQ ID NO:2.

5. The fusion protein of claim 1, wherein the single PSI domain is a Plexin B1 PSI domain; a Plexin B2 PSI domain; or a Plexin B3 PSI domain.

6. The fusion protein of claim 1, wherein the fusion protein has an amino acid sequence comprising SEQ ID NO:4 or SEQ ID NO:5.

7. The fusion protein of claim 1, wherein the fusion protein comprises (a) a Plexin B1 sema domain;(b) a single Plexins-Semaphorins-Integrins domain (PSI domain); and(c) a fragment crystallizable region (Fc region),

8. The fusion protein of claim 1, wherein the fusion protein comprises (a) a SEMA3C sema domain;(b) a single Plexins-Semaphorins-Integrins domain (PSI domain); and(c) an albumin,

9. A pharmaceutical composition comprising a fusion protein in combination with a physiologically acceptable carrier, wherein the fusion protein comprises: (a) a SEMA3C sema domain or Plexin B1 sema domain;(b) a single Plexins-Semaphorins-Integrins domain (PSI domain); and(c) a half life extending moiety, provided that when the sema domain is from SEMA3C then the half-life extending moiety is albumin, and provided that when the sema domain is from Plexin B1 then the half-life extending moiety is a fragment crystallizable region (Fc region) and the Fc region forms a dimer,provided that when the sema domain is from SEMA3C the fusion protein lacks an immunoglobulin-like domain.

10. The pharmaceutical composition of claim 9, wherein the fusion protein further comprises one or more of a linker and a hinge between the PSI domain and the half life extending moiety.

11. The pharmaceutical composition of claim 9, wherein the single PSI domain comprises SCAQHLDCASCLAHRDPYCG WCVLLGRCSRRSECSRGQGPEQ (SEQ ID NO: 1).

12. The pharmaceutical composition of claim 9, comprising an amount of the fusion protein sufficient to cause cell death of a cancer cell or to inhibit proliferation of the cancer cell.

13. The pharmaceutical composition of claim 12, wherein the cancer cell is a prostate cancer cell, a breast cancer cell, an ovarian cancer cell, a bladder cancer cell, a kidney cancer cell, a glioblastoma cell or an endometrial cancer cell.

14. The pharmaceutical composition of claim 13, wherein the cancer cell is a prostate cancer cell, and wherein the prostate cancer cell is an androgen receptor (AR) positive prostate cancer cell.

15. The pharmaceutical composition of claim 9, wherein the fusion protein has an amino acid sequence comprising SEQ ID NO:2.

16. The pharmaceutical composition of claim 9, wherein the single PSI domain is a Plexin B1 PSI domain; a Plexin B2 PSI domain; or a Plexin B3 PSI domain.

17. The pharmaceutical composition of claim 9, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5.

18. The pharmaceutical composition of claim 9, wherein the fusion protein comprises: (a) a Plexin B1 sema domain;(b) a single Plexins-Semaphorins-Integrins domain (PSI domain); and(c) a fragment crystallizable region (Fc region),

19. The pharmaceutical composition of claim 9, wherein the fusion protein comprises: (a) a SEMA3C sema domain;(b) a single Plexins-Semaphorins-Integrins domain (PSI domain); and(c) an albumin;

20. A method for treating cancer in a patient, the method comprising administering an effective amount of the fusion protein of claim 1 to the patient.

21. The method of claim 20, wherein the fusion protein further comprises one or more of a linker and a hinge between the single PSI domain and the half life extending moiety.

22. The method of claim 20, wherein the single PSI domain comprises SCAQHLDCASCLAHRDPYCG WCVLLGRCSRRSECSRGQGPEQ (SEQ ID NO:1).

23. The method of claim 20, wherein the cancer is prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer.

24. The method of claim 23, wherein the cancer is prostate cancer, and wherein the prostate cancer is an androgen receptor (AR) positive prostate cancer.

25. The method of claim 20, wherein the cancer is an androgen receptor (AR) positive prostate cancer and the effective amount of the fusion protein is sufficient for killing or inhibiting the proliferation of androgen receptor (AR) positive prostate cancer.

26. The method of claim 25, wherein the fusion protein further comprises one or more of a linker and a hinge between the PSI domain and the half life extending domain.

27. The method of claim 20, wherein the cancer is an androgen dependent prostate cancer, the method further comprises administering androgen deprivation therapy to the patient.

28. The method of claim 27, wherein administration of the androgen deprivation therapy and the fusion protein are initiated at about the same time; or wherein administration of the fusion protein is initiated after androgen deprivation therapy and before the androgen dependent prostate cancer becomes androgen independent.

29. The method of claim 27, wherein the androgen deprivation therapy comprises administering a luteinizing hormone-releasing hormone (LHRH) analog.

30. The method of claim 27, wherein the androgen deprivation therapy comprises administering anti-androgen treatment.

31. The method of claim 27, wherein the androgen deprivation therapy comprises administering an adrenal androgen inhibitor.

32. The method of claim 27, wherein the androgen deprivation therapy is surgical.

33. The method of claim 27, wherein the androgen deprivation therapy and the fusion protein are administered with one or more further therapeutic regimen(s).

34. The method of claim 33, wherein the therapeutic regimen is a chemotherapeutic regimen.

35. The method of claim 33, wherein the therapeutic regimen is a radiotherapeutic regimen.

36. The method of claim 20, wherein the fusion protein comprises SEQ ID NO:2.